<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Int J Mol Sci</journal-id><journal-id journal-id-type="iso-abbrev">Int J Mol Sci</journal-id><journal-id journal-id-type="pmc-domain-id">808</journal-id><journal-id journal-id-type="pmc-domain">ijms</journal-id><journal-id journal-id-type="publisher-id">ijms</journal-id><journal-title-group><journal-title>International Journal of Molecular Sciences</journal-title></journal-title-group><issn pub-type="epub">1422-0067</issn><publisher><publisher-name>Multidisciplinary Digital Publishing Institute  (MDPI)</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC11312000</article-id><article-id pub-id-type="pmcid-ver">PMC11312000.1</article-id><article-id pub-id-type="pmcaid">11312000</article-id><article-id pub-id-type="pmcaiid">11312000</article-id><article-id pub-id-type="pmid">39125737</article-id><article-id pub-id-type="doi">10.3390/ijms25158168</article-id><article-id pub-id-type="publisher-id">ijms-25-08168</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Discordant <italic toggle="yes">ALK</italic> Status in Non-Small Cell Lung Carcinoma: A Detailed Reevaluation Comparing IHC, FISH, and NGS Analyses</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0009-0009-9060-5348</contrib-id><name name-style="western"><surname>Tobi&#225;&#353;ov&#225;</surname><given-names initials="K">Katar&#237;na</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#8211; original draft</role><xref rid="af1-ijms-25-08168" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Barthov&#225;</surname><given-names initials="M">Martina</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><xref rid="af1-ijms-25-08168" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Jan&#225;kov&#225;</surname><given-names initials="&#x13D;">&#317;uboslava</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><xref rid="af1-ijms-25-08168" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Le&#353;kov&#225;</surname><given-names initials="K">Katar&#237;na</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><xref rid="af1-ijms-25-08168" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Farka&#353;ov&#225;</surname><given-names initials="A">Anna</given-names></name><xref rid="af2-ijms-25-08168" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-5421-9831</contrib-id><name name-style="western"><surname>Loderer</surname><given-names initials="D">Du&#353;an</given-names></name><xref rid="af3-ijms-25-08168" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Grend&#225;r</surname><given-names initials="M">Mari&#225;n</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Software" vocab-term-identifier="https://credit.niso.org/contributor-roles/software/">Software</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><xref rid="af3-ijms-25-08168" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-1153-1160</contrib-id><name name-style="western"><surname>Plank</surname><given-names initials="L">Luk&#225;&#353;</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><xref rid="af1-ijms-25-08168" ref-type="aff">1</xref><xref rid="af2-ijms-25-08168" ref-type="aff">2</xref><xref rid="c1-ijms-25-08168" ref-type="corresp">*</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name name-style="western"><surname>Kratzke</surname><given-names initials="RA">Robert Arthur</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-ijms-25-08168"><label>1</label>Department of Pathological Anatomy, University Hospital Martin, Jessenius Faculty of Medicine, Comenius University, 036 01 Martin, Slovakia; <email>tobiasova11@uniba.sk</email> (K.T.); </aff><aff id="af2-ijms-25-08168"><label>2</label>Martin&#8217;s Biopsy Center, Ltd., 036 01 Martin, Slovakia</aff><aff id="af3-ijms-25-08168"><label>3</label>Biomedical Centre Martin&#8212;BioMed Martin, Jessenius Faculty of Medicine, Comenius University, 036 01 Martin, Slovakia</aff><author-notes><corresp id="c1-ijms-25-08168"><label>*</label>Correspondence: <email>lukas.plank@uniba.sk</email></corresp></author-notes><pub-date pub-type="epub"><day>26</day><month>7</month><year>2024</year></pub-date><pub-date pub-type="collection"><month>8</month><year>2024</year></pub-date><volume>25</volume><issue>15</issue><issue-id pub-id-type="pmc-issue-id">468551</issue-id><elocation-id>8168</elocation-id><history><date date-type="received"><day>14</day><month>6</month><year>2024</year></date><date date-type="rev-recd"><day>19</day><month>7</month><year>2024</year></date><date date-type="accepted"><day>23</day><month>7</month><year>2024</year></date></history><pub-history><event event-type="pmc-release"><date><day>26</day><month>07</month><year>2024</year></date></event><event event-type="pmc-live"><date><day>10</day><month>08</month><year>2024</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-08-28 19:25:38.793"><day>28</day><month>08</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>&#169; 2024 by the authors.</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="ijms-25-08168.pdf"/><abstract><p><italic toggle="yes">ALK</italic> detection was performed on 2813 EGFR-unmutated NSCLC cases by simultaneous use of immunohistochemistry (VENTANA&#174; anti-ALK D5F3, Roche Molecular Systems, Inc., Rotkreuz, Switzerland) and fluorescence in situ hybridization with the ALK break apart and the ALK/EML4 fusion probe (ZytoVision, Bremerhaven, Germany). A total of 33 cases were positive discordant (FISH-positive, IHC-negative) and 17 cases were negative discordant (FISH-negative, IHC-positive). This study&#8217;s aim was to reevaluate the methods used and compare discordant samples to positive concordant samples in order to ellucidate the differences. FISH signal variants were examined and compared. Positive discordant cases featured one pattern of <italic toggle="yes">ALK</italic> rearrangement in 41.4%, two patterns in 48.3%, and three patterns in 10.3% of analysed samples, with a higher variability of detected patterns and a higher number of <italic toggle="yes">ALK</italic> copy gains. Positive concordant cases displayed one pattern of rearrangement in 82%, two patterns in 17.8%, and three patterns in 0.6% of analysed samples. The association between number of patterns and concordance/discordance was statistically significant (<italic toggle="yes">p</italic> &lt; 0.05). Eleven positive discordant and two negative concordant cases underwent NGS analysis, which resulted in identification of <italic toggle="yes">ALK</italic> fusion in one positive discordant and two negative discordant cases. Positive protein expression regardless of FISH result correlated more with a positive NGS result compared to samples with a positive FISH result with negative protein expression. FISH analysis was able to detect atypical or heterogenous patterns of rearrangement in a proportion of cases with negative protein expression, which may be associated with more extensive genetic alterations rather than true <italic toggle="yes">ALK</italic> rearrangement.</p></abstract><kwd-group><kwd>ALK-rearranged NSCLC</kwd><kwd>ALK discordance</kwd><kwd>ALK protein expression</kwd><kwd>non-small cell lung carcinoma</kwd></kwd-group><funding-group><award-group><funding-source>&#8220;Integrative strategy in development of personalized medicine of specified malignant tumours and its effect on quality of life&#8220;</funding-source><award-id>ITMS 313011V446</award-id></award-group><funding-statement>This research received funding from project ITMS 313011V446 &#8220;Integrative strategy in development of personalized medicine of specified malignant tumours and its effect on quality of life&#8220; to perform NGS analyses, currently not covered by health insurance in Slovakia.</funding-statement></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="sec1-ijms-25-08168"><title>1. Introduction</title><p>Treatment of non-small cell lung carcinoma (NSCLC) has gone through significant changes in the span of last two decades. Based on presence of oncogenic mutations, two categories of NSCLC have been established&#8212;the &#8220;oncogene-addicted&#8221; and &#8220;non-oncogene-addicted&#8221; NSCLC [<xref rid="B1-ijms-25-08168" ref-type="bibr">1</xref>], with separate guidelines for treatment.</p><p>One of the most frequent targetable genetic alterations in NSCLC is the rearrangement of the <italic toggle="yes">ALK</italic> gene, found in approximately 3&#8211;5% of all NSCLC cases [<xref rid="B2-ijms-25-08168" ref-type="bibr">2</xref>]. ALK protein is a transmembrane protein with intracytoplasmic tyrosine-kinase domain, which upon activation triggers the downstream cell signaling cascades regulating proliferation, differentiation, and migration of cells. Oncogenic alteration of the <italic toggle="yes">ALK</italic> gene is usually caused by a chromosomal split in intron 19 of the <italic toggle="yes">ALK</italic> gene and the subsequent fusion of the tyrosine-kinase domain corresponding part to another partner gene, causing production of large quantities of the chimeric intracytoplasmic ALK protein [<xref rid="B3-ijms-25-08168" ref-type="bibr">3</xref>] with aberrant activation independent of external stimuli. The second breaking point is usually localized within the <italic toggle="yes">EML4</italic> gene, leading to an intrachromosomal <italic toggle="yes">ALK::EML4</italic> inversion with currently more than 21 identified variants [<xref rid="B4-ijms-25-08168" ref-type="bibr">4</xref>]; other fusions, such as <italic toggle="yes">ALK::KIF5B</italic>, <italic toggle="yes">ALK::KLC1</italic>, or <italic toggle="yes">ALK::TPR</italic>, occur less often, in approximately 5% of cases [<xref rid="B5-ijms-25-08168" ref-type="bibr">5</xref>].</p><p><italic toggle="yes">ALK</italic>-rearranged NSCLC responds well to small molecule inhibitors of receptors with tyrosine-kinase activity (TKIs). First-generation TKI crizotinib has a superior response rate compared to cytotoxic chemotherapy and displays significantly better overall survival (OS) as first-line therapy [<xref rid="B6-ijms-25-08168" ref-type="bibr">6</xref>,<xref rid="B7-ijms-25-08168" ref-type="bibr">7</xref>]. Second-generation CNS-penetrant ALK-TKIs, including ceritinib, alectinib, and brigatinib, show even longer progression-free survival (PFS) compared to crizotinib and therefore are currently preferred in first-line treatment [<xref rid="B8-ijms-25-08168" ref-type="bibr">8</xref>,<xref rid="B9-ijms-25-08168" ref-type="bibr">9</xref>,<xref rid="B10-ijms-25-08168" ref-type="bibr">10</xref>,<xref rid="B11-ijms-25-08168" ref-type="bibr">11</xref>].</p><p><italic toggle="yes">ALK</italic> rearrangement detection has been performed mainly by immunohistochemistry (IHC) and in situ hybridization, nowadays with increasing demand for multiple gene analysis available through next-generation sequencing (NGS). Fluorescence in situ hybridization (FISH) allows detection of a split in the <italic toggle="yes">ALK</italic> gene on the chromosomal level; however, it is expensive, requires adequate quality of tissue, and expertise in interpretation of signal variants. <italic toggle="yes">ALK::EML4</italic> fusions tend to display a so-called short break pattern (less than two signal diameter), which can be interpreted as a false negative [<xref rid="B12-ijms-25-08168" ref-type="bibr">12</xref>], though using the ALK/EML4 fusion probe mitigates this pitfall.</p><p>IHC analysis performed with more sensitive rabbit monoclonal antibodies (e.g., D5F3, Ventana) has become a valuable counterpart to FISH and is currently approved as a screening method for <italic toggle="yes">ALK</italic> rearrangement, even being acceptable as an equivalent alternative in the case of FISH unavailability or failure [<xref rid="B1-ijms-25-08168" ref-type="bibr">1</xref>]. IHC is easier to interpret and cheaper; however, it cannot fully replace FISH as the method of choice [<xref rid="B13-ijms-25-08168" ref-type="bibr">13</xref>,<xref rid="B14-ijms-25-08168" ref-type="bibr">14</xref>,<xref rid="B15-ijms-25-08168" ref-type="bibr">15</xref>], mainly due to the rare occurrence of discrepancies: some cases are either positive discordant (FISH+, IHC&#8722;) or negative discordant (FISH&#8722;, IHC+). This can be partially attributed to preanalytical steps [<xref rid="B16-ijms-25-08168" ref-type="bibr">16</xref>], as well as post-translational changes and miscellaneous properties of the <italic toggle="yes">ALK</italic> protein produced by different rearrangement variants. A part of FISH negative cases can still be confirmed as <italic toggle="yes">ALK</italic> positive using another method [<xref rid="B17-ijms-25-08168" ref-type="bibr">17</xref>]. IHC seems to correlate with NGS more and potentially is even more sensitive [<xref rid="B18-ijms-25-08168" ref-type="bibr">18</xref>], although this can be attributed to technical challenges of FISH analysis. The simultaneous use of IHC and FISH is therefore still recommended [<xref rid="B19-ijms-25-08168" ref-type="bibr">19</xref>,<xref rid="B20-ijms-25-08168" ref-type="bibr">20</xref>], and whenever possible, discrepant cases should undergo analysis using NGS.</p><p>Discordance of ALK status has been a widely discussed topic, mainly due to clinical implications. Several case reports [<xref rid="B21-ijms-25-08168" ref-type="bibr">21</xref>,<xref rid="B22-ijms-25-08168" ref-type="bibr">22</xref>] and larger patient cohorts [<xref rid="B23-ijms-25-08168" ref-type="bibr">23</xref>] conclude that ALK expression even with negative FISH result was associated with the desirable response to TKI treatment. Some published studies prove that patients with a positive discordant result may respond inadequately compared to negative discordant patients (62% response rate compared to 100% response rate) [<xref rid="B24-ijms-25-08168" ref-type="bibr">24</xref>] or TKI treatment in positive discordant patients who are not confirmed as positive by NGS may be completely ineffective [<xref rid="B25-ijms-25-08168" ref-type="bibr">25</xref>]. However, negative discordance (FISH&#8722;, IHC+) can predict worse overall survival [<xref rid="B26-ijms-25-08168" ref-type="bibr">26</xref>] compared to concordant patients.</p><p>Our department performs the analysis of <italic toggle="yes">ALK</italic> status using IHC and FISH simultaneously, which over time naturally led to the accumulation of discordant cases. Our main concern was the reevaluation of methods used and finding possible explanations for the discrepancies. FISH analysis occasionally produced some unusual variants reports, leading us to the question whether the <italic toggle="yes">ALK</italic> discrepancies can be partially elucidated by comparing the FISH signal variants found in discordant cases to positive concordant samples. Furthermore, we aimed to validate these observations by comparing with NGS performed on a proportion of our cohort as a part of a pilot study.</p></sec><sec sec-type="results" id="sec2-ijms-25-08168"><title>2. Results</title><sec id="sec2dot1-ijms-25-08168"><title>2.1. Concordance and Discordance between FISH and IHC</title><p>ALK detection using IHC and FISH simultaneously was successfully performed on 2683 samples. In 130 samples, one or both methods failed due to material limitations and were not further included into our study.</p><p>A total of 2444 samples were negative using both FISH and IHC, so-called negative concordant. A total of 184 cases were positive concordant; 38 cases were positive for <italic toggle="yes">ALK</italic> rearrangement using FISH, but negative for ALK protein expression and were labeled as positive discordant. In 9 of them, material quantity and quality were sufficient to repeat the IHC analysis. 5 cases displayed the so-called &#8220;dot-like&#8221; positivity and were reclassified as positive concordant. In 4 cases, the repeated IHC was still negative. The final number of positive concordant cases was 189, and the number of positive discordant cases was 33. A total of 17 cases were negative for <italic toggle="yes">ALK</italic> rearrangement with positive ALK protein expression and were labeled as negative discordant. Reevaluation of FISH did not reveal any false negatives.</p><p>Discordant cases altogether comprised 1.86% of all cases, with 1.23% being positive discordant and 0.63% being negative discordant. Out of all FISH-positive cases, 14.9% were positive discordant. Out of all FISH-negative cases, 0.7% were negative discordant. Sensitivity of FISH was calculated to be 91.7%, and specificity of FISH was 98.6%.</p></sec><sec id="sec2dot2-ijms-25-08168"><title>2.2. Demographic Distribution</title><p>The population group consisted of 1716 male patients and 967 female patients (<xref rid="ijms-25-08168-t001" ref-type="table">Table 1</xref>), with age ranging from 23 to 91, with the mean of 65 years and median 66 years. NSCLC diagnosis occurred most frequently in patients in the sixth decade.</p><p>The overall frequency of <italic toggle="yes">ALK</italic> rearrangement was 5.5% in the male population, 13.1% in the female population, and 8.3% regardless of gender. <italic toggle="yes">ALK</italic> rearrangement was most prevalent in population of young patients, with peak incidence in female patients under 40 (7 out of 18 cases) and under 50 (15 out of 58 analyzed cases), as well as male patients under 50 years (22 out of 91 cases). With increasing age, the prevalence of <italic toggle="yes">ALK</italic> rearrangement became progressively lower but was more frequent in the female population in every age group. Negative discordant cases were found almost exclusively in the female population (14 out of 17 cases); positive discordant cases showed a slight male predominance (20 out of 33 cases).</p></sec><sec id="sec2dot3-ijms-25-08168"><title>2.3. Histopathology</title><p>In the positive discordant cohort, material limitations did not allow further specification than the &#8220;adenocarcinoma, NOS&#8221; category in 11 out of 33 cases (33.33%). The most frequently occurring types were solid predominant adenocarcinoma in four cases (12.12%), then G3 adenocarcinoma and metastatic adenocarcinoma in three cases (9.09%). Mucin production was especially noted in the report in 2 cases (6.06%), was not detected in 3 cases (9.09%), and was not specified in 28 cases (84.85%).</p><p>In the negative discordant cohort, the category &#8220;adenocarcinoma, NOS&#8221; was used in four cases (23.53%), equally in number as solid predominant adenocarcinoma (23.53%). Other subtypes did not occur particularly frequently. Mucin production was specially noted in the report in 1 case (5.88%), was not detected in 2 cases (11.76%) and was not specified in 14 cases (82.35%).</p><p>In the positive concordant cohort, &#8220;adenocarcinoma, NOS&#8221; was used in 57 cases (30.16%), followed equally by acinar predominant, solid predominant, and metastatic adenocarcinoma, each comprising 21 cases (11.11%). &#8220;Adenocarcinoma, NOS, mucin producing&#8221;, and mucinous adenocarcinoma accounted for eight cases each (4.23%), followed by cases classified as micropapillary predominant adenocarcinoma and G3 adenocarcinoma, with six cases for each category (3.17%), and signet ring cell adenocarcinoma with four cases (2.12%). Mucin production was noted in at least one component in 38 cases (20.10%), not detected in 6 cases (3.17%), and not specified in 145 cases (76.72%) (<xref rid="ijms-25-08168-t002" ref-type="table">Table 2</xref>).</p></sec><sec id="sec2dot4-ijms-25-08168"><title>2.4. Comparison of ALK Copy Number Gains in ALK Concordant and Discordant Samples</title><p>The positive discordant cohort had 3 or less <italic toggle="yes">ALK</italic> copies in 12 out of 33 cases (36.36%), 4 to 6 <italic toggle="yes">ALK</italic> copies in 8 cases (24.24%), 7 to 9 <italic toggle="yes">ALK</italic> copies in 6 cases (18.18%), and 10+ <italic toggle="yes">ALK</italic> copies in 7 cases (21.21%). The negative discordant cohort featured three or less <italic toggle="yes">ALK</italic> copies in 11 cases (64.7%), 4 to 6 <italic toggle="yes">ALK</italic> copies in 2 cases (11.76%), 7 to 9 <italic toggle="yes">ALK</italic> copies in 1 case (5.88%), and 10+ <italic toggle="yes">ALK</italic> copies in 3 cases (17.65%). The positive concordant cohort displayed 3 or less <italic toggle="yes">ALK</italic> copies in 129 cases (68.25%), 4 to 6 <italic toggle="yes">ALK</italic> copies in 40 cases (21.16%), 7 to 9 <italic toggle="yes">ALK</italic> copies in 19 cases (10.05%), and 10+ <italic toggle="yes">ALK</italic> copies in 1 case (0.53%) (<xref rid="ijms-25-08168-t003" ref-type="table">Table 3</xref>).</p></sec><sec id="sec2dot5-ijms-25-08168"><title>2.5. FISH Pattern Distribution in Positive Discordant and Positive Concordant Samples</title><p>A total of 197 samples previously tested with ALK break apart probe were analyzed with ALK/EML4 fusion probe and classified according to their predominant pattern of rearrangement as described in <xref rid="sec4-ijms-25-08168" ref-type="sec">Section 4</xref>. The cohort consisted of 29 positive discordant samples and 168 positive concordant samples.</p><sec id="sec2dot5dot1-ijms-25-08168"><title>2.5.1. Positive Discordant Samples</title><p>In 13 samples (44.8%), the positive result was a combination of several signal variants each below 15%. In five of them, it was possible after elimination of sectioning artifacts to identify one pattern of rearrangement (all inversion). In seven samples, two patterns were identified, and in one sample, three patterns were found. In 16 samples (51.8%), at least one pattern of rearrangement reached the cut off. Seven of them were evaluated as containing one rearrangement pattern (five cases of inversion, two cases of 5&#8242; deletion); in seven samples, two patterns of rearrangement were identified, and in two samples, three patterns of rearrangement were identified (<xref rid="ijms-25-08168-t004" ref-type="table">Table 4</xref>).</p><p>One pattern was overall identified in 12 out of 29 samples (41.4%), two patterns were found in 14 samples (48.3%) and three patterns in 3 samples (10.3%). Inversion was identified in 10 out of 12 samples with single rearrangement pattern (83.3%). Another single rearrangement pattern was 5&#8242; deletion, in 2 cases (16.7%). Interstitial deletion and translocation did not occur as single identified patterns, only in combinations.</p><p>Out of two pattern combinations, variants featuring mainly 5&#8242; deletion were present in 6 out of 14 samples (42.8%), interstitial deletion as the predominant pattern was found in 4 samples (28.6%), inversion in 3 samples (21.4%), and translocation in 1 sample (7.1%). Three samples with three rearrangement patterns all contained 5&#8242; deletion combined with translocation and inversion (in that order of percentage) (<xref rid="ijms-25-08168-f001" ref-type="fig">Figure 1</xref>).</p></sec><sec id="sec2dot5dot2-ijms-25-08168"><title>2.5.2. Positive Concordant Samples</title><p>In two samples (1.2%), the positive result was a combination of several signal variants each below 15%, which were, however, identified as resulting from inversion. In 166 cases (98.8%), at least one signal variant met or exceeded the 15% cut-off. A single pattern of rearrangement was overall found in 137 out of 168 samples (81.5%). A total of 30 samples (17.8%) were classified as containing two patterns. One sample featured three rearrangement patterns (0.6%) (<xref rid="ijms-25-08168-t004" ref-type="table">Table 4</xref>). Samples with one pattern identified featured almost exclusively inversion in 133 samples. Four samples (3%) displayed the interstitial deletion pattern. Translocation and 5&#8242; end deletion did not occur as a single pattern, only in combinations.</p><p>A total of 30 samples had a combination of two patterns, with the most frequent one being interstitial deletion and inversion in 21 samples (70%), followed by 5&#8242; deletion coupled with interstitial deletion in four samples (13.3%), as well as translocation combined with inversion in three samples (10%). Interstitial deletion combined with translocation, and the reverse order variant translocation combined with interstitial deletion, were found in one case (3.3%) each. One sample with three identified patterns featured 5&#8242; deletion, translocation, and inversion (<xref rid="ijms-25-08168-f001" ref-type="fig">Figure 1</xref>).</p></sec><sec id="sec2dot5dot3-ijms-25-08168"><title>2.5.3. Statistical Analysis of Pattern Distribution</title><p>There was a statistically significant association (<italic toggle="yes">p</italic>-value 0.0000055) between the type of sample (concordant/discordant) and variant of FISH signal (three patterns). Using the standard calibration of Cramer&#8217;s V for 2 degrees of freedom, the association may be judged strong (Cramer&#8217;s V is 0.37, with 95% confidence interval (0.24, 0.51)). Pattern frequency did not show a statistically significant association between the type of sample (concordant/discordant) (<xref rid="app1-ijms-25-08168" ref-type="app">Supplementary Materials File S1</xref>).</p></sec></sec><sec id="sec2dot6-ijms-25-08168"><title>2.6. NGS Analysis</title><p>NGS analysis was successfully performed on 75 samples: 58 negative concordant, 4 positive concordant, 11 positive discordant, and 2 negative discordant cases. NGS did not identify <italic toggle="yes">ALK</italic> fusion in any of the negative discordant cases (other alterations, not listed in this publication, were found). NGS identified <italic toggle="yes">ALK::EML4</italic> fusion in three positive cases and cases and <italic toggle="yes">HIP::ALK</italic> fusion in one positive concordant case. In 10 positive discordant cases, <italic toggle="yes">ALK</italic> fusion was not detected, and one case resulted in identification of <italic toggle="yes">ALK::EML4</italic> fusion transcript. In two negative discordant samples, NGS detected <italic toggle="yes">ALK</italic> fusion transcripts (<italic toggle="yes">ALK::EML4</italic> and <italic toggle="yes">ALK::CSFT3</italic>) (<xref rid="ijms-25-08168-t005" ref-type="table">Table 5</xref>).</p></sec></sec><sec sec-type="discussion" id="sec3-ijms-25-08168"><title>3. Discussion</title><p>Our main concern was to reevaluate the results of the applied tests of samples with discordant results and reevaluate correct interpretations of all the analyses. In the second step, comparison between methods was performed. This process revealed striking differences between positive discordant and positive concordant cases.</p><p>FISH patterns of rearrangement in the positive concordant cohort almost always (98.8%) reached levels above the cut-off value and consisted mainly of one common pattern of rearrangement (81.5%) identified in all positive nuclei. The positive discordant cohort partially (44.8%) consisted of cases where the positive result was reached by a combination of signal variants below the 15% cut-off. Higher variability in number of rearrangement patterns was also recorded (41.4% cases had one rearrangement pattern, two patterns were found in 48.3% samples and three patterns in 10.3% of samples), which was proven to be statistically significant. Heterogeneity of <italic toggle="yes">ALK</italic> rearrangement in positive discordant samples might be therefore responsible for the lack of ALK protein expression, and the ALK status should be evaluated by another method.</p><p>The positive concordant group showed high predominance of tumor samples featuring the classic <italic toggle="yes">ALK::EML4</italic> inversion, either as the single pattern (97% of samples with one pattern identified and 79.1% of all positive concordant samples) or very frequently coupled with interstitial deletion (70% of samples with two patterns identified). In contrast, inversion was the most frequently occurring single pattern in positive discordant samples as well (83.3% of cases with one pattern identified), but overall, it comprised only approximately over a third of all positive discordant cases.</p><p>5&#8242; deletion never occurred on its own in the positive discordant group, but it represented the main rearrangement pattern in 5 out of 31 samples with two or three identified patterns (16.1%). In the positive discordant group, it was found as the only pattern in two cases, and as the main pattern in 9 out of 17 (52.9%) samples with two or more identified patterns of rearrangement.</p><p>The FISH result featuring the isolated 5&#8216; orange signal with negative ALK protein expression may signify a false positive case, as was examined in a study by Gao et al. [<xref rid="B27-ijms-25-08168" ref-type="bibr">27</xref>], in which IHC-negative patients with this FISH signal variant did not fit into the typical profile of <italic toggle="yes">ALK</italic>-positive patients, with older age at diagnosis and more extensive smoking history. The FISH result was estimated to be caused by structural variants affecting the 5&#8242; binding site, associated with higher genomic instability of the tumor typical for prolonged smoking; therefore, it likely did not represent true <italic toggle="yes">ALK</italic> rearrangement. Clav&#233; et al. [<xref rid="B28-ijms-25-08168" ref-type="bibr">28</xref>] describe two IHC-negative cases with a predominant 5&#8242; deletion signal that tested negative for <italic toggle="yes">ALK</italic> fusion using NGS, with the recommendation to always retest this particular rearrangement variant. A similar finding was reported by Dacic et al. [<xref rid="B29-ijms-25-08168" ref-type="bibr">29</xref>], where NGS confirmed <italic toggle="yes">ALK</italic> fusion only in 4 out of 10 cases with 5&#8242; end deletion pattern only, while all showed IHC negativity.</p><p>IHC-positive cases, regardless of FISH status, tended to have fewer <italic toggle="yes">ALK</italic> CNG, as seen in 129 (68.25%) positive concordant cases, compared to 12 (36.36%) positive discordant cases. Multiple copies of <italic toggle="yes">ALK</italic> can be caused by <italic toggle="yes">ALK</italic> amplification or polysomy, but neither variant shows any clinical significance for indication of TKI treatment [<xref rid="B30-ijms-25-08168" ref-type="bibr">30</xref>]. Increased CNG likely comes from early genetic events triggered by cigarette smoking, independent of true <italic toggle="yes">ALK</italic> rearrangement, and is associated with genomic instability and more aggressive biological behavior, as well as potential higher sensitivity to chemotherapy [<xref rid="B31-ijms-25-08168" ref-type="bibr">31</xref>,<xref rid="B32-ijms-25-08168" ref-type="bibr">32</xref>], and also including one of the mechanisms of crizotinib resistance both in vitro and in patients progressing on TKI treatment [<xref rid="B33-ijms-25-08168" ref-type="bibr">33</xref>,<xref rid="B34-ijms-25-08168" ref-type="bibr">34</xref>]. Lower CNG in IHC-positive cases may indicate a more stable genomic profile compared to higher heterogeneity of positive discordant cases.</p><p>Cases with a notable presence of multiple components were described as such in the FISH report, and in our cohort were found predominantly in the positive discordant group, including 4 out of 13 positive discordant samples re-tested with NGS (cases 6, 9, 10, and 11). In these cases, either the <italic toggle="yes">ALK</italic> rearranged part represented only a small component of the overall tumor mass (cases 9 and 11), or these tumors contained two different components (adenocarcinoma and squamous cell carcinoma for case 6, well-differentiated and poorly differentiated component in case 10). The pattern of rearrangement included 5&#8216; end deletion (case 9), inversion (case 6, only adenocarcinoma component) and translocation with inversion (poorly differentiated area of case 10). A small part of the tumor cells may display alterations of the <italic toggle="yes">ALK</italic> locus, but its clinical significance and targetability by TKIs remains questionable. The patients&#8217; age in this subgroup of four patients (two male patients aged 63 and 78 and two female patients aged 70 and 79) also fell outside of the typical profile of ALK-positive patients; however, this parameter cannot be reliably used to determine <italic toggle="yes">ALK</italic> status. It is worth noting, though, that NGS analysis did not detect <italic toggle="yes">ALK</italic> fusion in any of these cases.</p><p>Out of 11 positive discordant cases tested with NGS, only one case (Case 3, <xref rid="ijms-25-08168-t005" ref-type="table">Table 5</xref>) revealed by NGS the <italic toggle="yes">ALK::EML4</italic> fusion transcript, and in all the other the NGS did not demonstrate <italic toggle="yes">ALK</italic> fusion. In comparison, <italic toggle="yes">ALK</italic> fusion was identified in two out of two negative discordant cases tested by NGS. One case (Case 12, <xref rid="ijms-25-08168-t004" ref-type="table">Table 4</xref>) featured predominantly an unusual 3&#8242; deletion pattern in 74% of evaluated nuclei. The 3&#8242; end of the hybridization probe binds to the tyrosine-kinase domain of the <italic toggle="yes">ALK</italic> gene necessary for activation of signal pathways; therefore, this alteration has uncertain clinical implications. Although the <italic toggle="yes">ALK</italic> locus was obviously altered in this sample and ALK protein expression was detected, it could not be classified as <italic toggle="yes">ALK</italic> positive under valid guidelines. However, NGS analysis revealed <italic toggle="yes">ALK::EML4</italic> fusion transcript and <italic toggle="yes">KLF7::EML4</italic> fusion as an additional finding.</p><p>NGS analysis in our cohort corresponded more with positive protein IHC expression than with FISH results, and similar results were also reported by Lin et al. [<xref rid="B18-ijms-25-08168" ref-type="bibr">18</xref>]. We might agree with the authors that it does not imply FISH to be less reliable, but that it rather points out the technical challenges of interpreting FISH and higher requirements for tissue quality to be eligible for testing. Our own experience in detailed analysis of all occurring signal variants offers a plausible explanation: FISH might be able to detect alterations in <italic toggle="yes">ALK</italic> locus associated with more extensive mutational profile. It is not entirely correct to consider these FISH results as false positives, if the method is performed adequately and interpreted correctly, but notable heterogeneity in detected rearrangement patterns, along with increased <italic toggle="yes">ALK</italic> CNGs in cases with negative ALK protein expression, can indicate more severe genomic alterations in the analyzed sample. All such cases should be therefore verified using NGS.</p></sec><sec id="sec4-ijms-25-08168"><title>4. Materials and Methods</title><p>A team composed of the Pathology Department of JFM CU and UH Martin and Martin&#8217;s Biopsy Center, Ltd., performed the detection of ALK protein expression using D5F3 antibody in 2813 NSCLC specimens, with all EGFR unmutated as examined by RT-PCR, as a part of the standard diagnosis algorithm. FFPE samples of either primary metastatic NSCLC were sent from other departments to undergo further molecular analysis to detect relevant predictive biomarkers of either targeted treatment and/or immunotherapy, including <italic toggle="yes">ALK</italic>, <italic toggle="yes">ROS-1</italic>, <italic toggle="yes">MET</italic>, <italic toggle="yes">RET,</italic> and <italic toggle="yes">NTRK1/2/3</italic> alterations and PDL-1 status. <italic toggle="yes">ALK</italic> rearrangement was tested by two standard methods: on the level of protein expression by IHC, and on the cytogenetic level using FISH. Discordant cases were carefully evaluated, and a small fraction of cases was additionally analyzed using NGS as a part of a pilot study.</p><sec id="sec4dot1-ijms-25-08168"><title>4.1. Immunohistochemistry</title><p>Immunohistochemical analysis of ALK protein expression was performed on 2813 of 3&#8211;4 &#181;m thick FFPE sections using monoclonal antibody VENTANA anti-ALK (clone D5F3, Roche Molecular Systems, Inc., Rotkreuz, Switzerland) on the BenchMark GX platform (Roche Molecular Systems, Inc., Rotkreuz, Switzerland). The analysis was realized according to the protocol recommended by the manufacturer. Sections were kept in the thermostat at 37 &#176;C all night and then were placed into BenchMark GX. After staining, sections were rinsed in running water for 10 min, dehydrated with graded alcohol and xylene, and coverslipped.</p><p>IHC quality control was performed through QuiP (Qualitatssicherungs-Initiative Pathologie GmbH, Berlin, Germany). Internal control was a part of every analyzed slide, using tissue from another <italic toggle="yes">ALK</italic>-positive case, which was exchanged regularly when the block aged. The whole slide was stained, but only the tumor area was evaluated for ALK protein expression. The outcomes were evaluated semiquantitatively according to the following criteria: the presence of strong diffuse granular cytoplasmic staining (2+, 3+). In the reevaluation stage, the so-called dot-like positivity was also labelled as positive. No staining, weak cytoplasmic staining (1+), or so-called stippled pattern were all interpreted as negative.</p></sec><sec id="sec4dot2-ijms-25-08168"><title>4.2. Fluorescence In Situ Hybridization</title><sec><title>FISH Analysis</title><p>FISH analysis was performed on 3&#8211;4 &#181;m thick formalin-fixed paraffin-embedded (FFPE) tissue sections using ZytoLight<sup>&#174;</sup>SPEC ALK Dual Color Break Apart Probe (ZytoVision, GmbH, Bremerhaven, Germany). FFPE specimens were processed manually using a ZytoLight<sup>&#174;</sup>FISH-Tissue Implementation Kit according to the manufacturer&#8217;s instructions. Results were analyzed using a fluorescence BX61 microscope (Olympus, Tokyo, Japan) with the support of the software Lucia FISH v.3.1 (Laboratory Imaging, Prague, Czech Republic).</p><p><italic toggle="yes">ALK</italic> rearrangement was scored according to the valid guidelines [<xref rid="B35-ijms-25-08168" ref-type="bibr">35</xref>]. In all cases with sufficient tumor cell count, 100 nuclei were enumerated. If material was critically limited, then the evaluated tumor cell count was lower than 100 but had to include minimally 50 cells. Cases with less than 50 cells were excluded from our study.</p><p>The presence of two isolated signals (3&#8242; orange signal and 5&#8242; green signal) at least two-signal diameter apart and/or a single 3&#8242;-isolated orange signal were marked as positive, demonstrating a split in the structure of <italic toggle="yes">ALK</italic> gene. An orange/green fusion signal indicated an intact <italic toggle="yes">ALK</italic> locus, andtherefore it was interpreted as negative. Specimens with &#8805;15% of positive cells were classified as positive for <italic toggle="yes">ALK</italic> rearrangement, while cases with &lt;15% were classified as negative. All positive and some equivocal samples displaying the so-called short break pattern (less than two-signal diameter) were retested again using the ZytoLight <sup>&#174;</sup>SPEC ALK/EML4 TriCheck&#8482;Probe. <italic toggle="yes">ALK</italic> rearrangement was scored according to the manufacturer&#8217;s instructions [<xref rid="B36-ijms-25-08168" ref-type="bibr">36</xref>].</p><p><italic toggle="yes">ALK</italic> copy number gain (CNG) was evaluated using the ALK break apart probe, without distinction between polysomy and amplification, displayed as cells with multiple copies of an intact <italic toggle="yes">ALK</italic> locus (multiple fusion signals in a single nucleus). Four categories were established: &#8220;three or less <italic toggle="yes">ALK</italic> CNGs&#8221;, &#8220;4&#8211;6 <italic toggle="yes">ALK</italic> CNGs&#8221;, &#8220;7&#8211;9 <italic toggle="yes">ALK</italic> CNGs&#8221;, and &#8220;10+ <italic toggle="yes">ALK</italic> CNGs&#8221;.</p><p>Positive discordant and positive concordant cases retested with ALK/EML4 fusion probe were compared in terms of FISH rearrangement variants.</p><p>Translocation with other than the <italic toggle="yes">EML4</italic> partner was indicated by the presence of (a) isolated 3&#8242; orange signal and isolated 5&#8242; green signal co-localizing with blue signal (O/GB); (b) isolated 3&#8242; orange signal and isolated 5&#8242; green signal (O/G); or (c) isolated 3&#8242; orange signal, isolated 5&#8242; green signal, and isolated blue signal (O/G/B).</p><p>ALK/EML4 inversion pattern included one or more of the following variants: (a) isolated 3&#8242; orange signal co-localizing with blue signal and isolated 5&#8242; green signal co-localizing with blue signal (<xref rid="ijms-25-08168-f002" ref-type="fig">Figure 2</xref>) (OB/GB); (b) isolated 3&#8242; orange signal co-localizing with blue signal and isolated 5&#8242; green signal (OB/G); (c) isolated 3&#8242;orange signal co-localizing with blue signal, isolated blue signal, and isolated 5&#8242; green signal (OB/B/G); or (d) inversion with partial <italic toggle="yes">ALK</italic> gene deletion, represented by isolated 3&#8242; orange signal co-localizing with blue signal and another isolated blue signal (OB/B).</p><p>The 5&#8242; end deletion of the <italic toggle="yes">ALK</italic> gene was represented by two variants: (a) isolated 3&#8242; orange signal, loss of 5&#8242; green signal (O), or (b) isolated 3&#8242; orange signal, isolated blue signal, loss of 5&#8242;green signal (O/B).</p><p>Interstitial deletion of the <italic toggle="yes">ALK</italic> gene was indicated by the presence of an isolated 3&#8242; orange signal co-localizing with a blue signal (OB).</p><p>When analyzing samples, either at least one signal combination on its own reached above the 15% cut-off, or the positive result was composed of several rearrangement variants, each with less than 15% of positivity, but at the very least found in 4% of rearranged nuclei (<xref rid="ijms-25-08168-f003" ref-type="fig">Figure 3</xref>).</p><p>The predominant pattern of rearrangement was the signal combination with the highest percent of positivity in rearranged cells. All other identified patterns were then evaluated based on whether or not they could have been derived from the predominant pattern. If the minority pattern was less complex, featured less signals, or its configuration was a part of the predominant pattern, it was not considered a secondary pattern, but most likely a result of tissue sectioning. If the minority pattern was found in at least 4% of rearranged nuclei, was more complex, featured more fluorescent signals, or its structure could not have been derived from the predominant pattern, it was considered a secondary (or tertiary) pattern of rearrangement. Details and examples of this assortment can be found in <xref rid="app1-ijms-25-08168" ref-type="app">Supplementary Materials File S2</xref>.</p></sec></sec><sec id="sec4dot3-ijms-25-08168"><title>4.3. Next-Generation Sequencing</title><p>Sequencing was performed with the panel TruSight Oncology 500 Assay (Illumina, San Diego, CA, USA), enabling simultaneous analysis of DNA and RNA extracted from the same sample. This assay provides detection of SNVs and indels in 523 cancer-related genes, CNVs of 69 genes, gene fusions and splice variant of 55 driver genes, and immunotherapy biomarkers that rely on the analysis of multiple genomic loci such as tumor mutational burden (TMB) and microsatellite instability (MSI).</p><p>Tissue was sectioned into 4 to 6 10 &#956;m thick slices and deparaffinized using Qiagen solution. Isolated DNA was treated with RNAse A to eliminate contamination from RNA; similarly, RNA was treated with DNAse A to ensure high purity of nucleic acids.</p><p>DNA quantity was measured with a Qubit dsDNA BR kit (Invitrogen (Carlsbad, CA, USA), Thermo Fisher Scientific (Waltham, MA, USA)) on the Qubit 4 Flurometer platform, (Thermo Fisher Scientific, Waltham, MA, USA). The minimal required amount of DNA was 80 ng/sample; samples that did not meet this criterion were excluded. Quality control was performed with Infinium FFPE QC kit (Illumina, USA) according to the manufacturer&#8217;s guidelines.</p><p>RNA quality was measured with an RNA 6000 Nano kit (Agilent, Santa Clara, CA, USA), and the level of DV200 was assessed. This number corresponded to the percentage of RNA fragments with length greater than 200 bp. DV200 &lt; 30% signified a high level of RNA degradation not suitable for NGS analysis, and these samples were excluded. Samples with a concentration of RNA higher than 10 ng/&#956;L and DV200 &gt; 30% were used for the preparation of libraries.</p><p>According to the manufacturer&#8217;s instruction for Illumina TruSight 500 Oncology Assay, 16 libraries were manually processed, containing 8 DNA and 8 cDNA. Finally, libraries with concentration &gt;3 ng/&#181;L were normalized, pooled, and loaded on a NextSeq 550Dx (Illumina, San Diego, CA, USA). The paired-end sequencing runs (2 &#215; 101 bp) were performed in high output mode with a High Output Kit v2.5 (300 Cycles). Output from NGS was subjected to bioinformatic processing by Illumina LocalApp ver. 2.2.0. There is no cutoff on variant allele frequency (VAF) in the LocalApp pipeline. The cutoff there is set in a dynamic manner, depending on loci and sample quality, and it can be as low as 2&#8211;3 mutant reads. In addition, there are two quality scores: AQ (variant artifact adjusted quality score; <italic toggle="yes">p</italic>-value against baseline samples) and LQ (likelihood ratio quality score; sample specific <italic toggle="yes">p</italic>-value). Point mutations were identified as one nucleotide, insertions as the length of 18 bp, and deletion between 10 and 25 bp.</p><p>For the fusion calling, the unique reads were used. In order for a fusion to be called with high confidence, at least 5 unique reads were needed. Concerning the copy number variation (CNV), the TSO500 panel allows for CNV calling in 59 genes. Each gene had a different noise profile. For this reason, each gene had specific thresholds for calling amplifications and deletions. Samples with a tumor content above 20% were analyzed in our study (for amplification, it means 14 copies at the 20% tumor purity).</p><p>The results of bionformatic processing were afterwards annotated by the PierianDX Clinical Genomics Workspace (CGW). The annotation involves, among other things, ranking of the called SNVs, CNVs, and fusions into tiers, according to standards and guidelines for the interpretation and reporting of sequence variants in cancer: a joint consensus recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists [<xref rid="B37-ijms-25-08168" ref-type="bibr">37</xref>].</p></sec><sec id="sec4dot4-ijms-25-08168"><title>4.4. Comparison of IHC and FISH</title><p>Sensitivity of FISH was calculated as the number of positive concordant results divided by positive concordant and FISH-negative discordant cases. Specificity was calculated as the number of negative concordant results divided by negative discordant and FISH-positive discordant results. Concordance between <italic toggle="yes">ALK</italic> rearrangement and ALK protein expression was performed. Demographic characteristics of population groups were evaluated, and differences in <italic toggle="yes">ALK</italic> rearrangement among population groups were assessed.</p><p>FISH results of positive concordant and FISH-positive discordant cases were further sorted according to patterns detectable using ALK/EML4 fusion probe. The total number of detected patterns was recorded in FISH-positive concordant and FISH-positive discordant cases, and the predominant pattern of rearrangement was identified. If the sample contained more patterns, their combination was also documented. <italic toggle="yes">ALK</italic> CNG was compared between positive concordant and all discordant cases.</p></sec><sec id="sec4dot5-ijms-25-08168"><title>4.5. Statistical Analysis</title><p>Data were explored and analyzed in R [<xref rid="B1-ijms-25-08168" ref-type="bibr">1</xref>], ver. 4.0.5, with the aid of libraries [<xref rid="B38-ijms-25-08168" ref-type="bibr">38</xref>,<xref rid="B39-ijms-25-08168" ref-type="bibr">39</xref>,<xref rid="B40-ijms-25-08168" ref-type="bibr">40</xref>,<xref rid="B41-ijms-25-08168" ref-type="bibr">41</xref>]. Contingency tables were visualized by mosaicplot. The null hypothesis of no association between two factors was tested by Fisher&#8217;s exact test. Effect size was measured by Cramer&#8217;s V, and its uncertainty was quantified by a 95% double-sided chi-squared confidence interval. Where there was row of 0 frequencies in a contingency table, the Laplace smoothing was applied to the table prior to hypothesis testing.</p></sec></sec><sec sec-type="conclusions" id="sec5-ijms-25-08168"><title>5. Conclusions</title><p>Our department performed simultaneous detection of <italic toggle="yes">ALK</italic> rearrangement using both FISH and IHC, which aided in more reliable detection of <italic toggle="yes">ALK</italic> rearrangement in case of failure of one of the methods. FISH results are interpreted with detailed description of all occurring patterns and CNGs, and a thorough look at the ALK rearrangement variants might contribute to the explanation of the lacking protein expression in positive discordant cases.</p><p>Positive concordant samples tended to display the classic inversion and also show less variability in detected variants, suggesting that the genomic profile of the tumor population is more stable compared to the IHC-negative cases, which correlates with the typical demographic group of younger, non-smoker patients. Positive discordant cases were associated with a higher variability of detected rearrangement variants, as well as with the 5&#8242; deletion pattern. FISH-positive cases without ALK protein expression displaying one of these characteristics should be promptly verified with another method.</p><p>NGS results seem to show a correlation with ALK-protein-positive expression in our limited cohort. In conclusion, the simultaneous use of IHC and FISH, as is the standard in many departments including ours, allows for the selection of the highest number of patients eligible for targeted treatment. Further implementation of NGS is crucial in improving diagnosis and detection of other predictive biomarkers and indicating the best possible treatment for NSCLC patients.</p></sec></body><back><fn-group><fn><p><bold>Disclaimer/Publisher&#8217;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><app-group><app id="app1-ijms-25-08168"><title>Supplementary Materials</title><p>The following supporting information can be downloaded at <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.mdpi.com/article/10.3390/ijms25158168/s1">https://www.mdpi.com/article/10.3390/ijms25158168/s1</uri>.</p><supplementary-material id="ijms-25-08168-s001" position="float" content-type="local-data" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ijms-25-08168-s001.zip" position="float" orientation="portrait"/></supplementary-material></app></app-group><notes><title>Author Contributions</title><p>Conceptualization, K.T., M.B., and L.P.; FISH evaluation, M.B. and &#317;.J.; IHC analysis, L.P. and A.F.; NGS analysis, D.L. and M.G.; statistical analysis, M.G.; data curation, K.T.; writing&#8212;original draft preparation, K.T.; writing&#8212;review and editing, K.T., M.B., K.L., and L.P. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>Ethical review and approval were waived for this study due to the retrospective analysis of the fully anonymized data used in the study. The consent to use biological material for diagnostic and research purposes was included during admittance to the healthcare facility.</p></notes><notes><title>Informed Consent Statement</title><p>Informed consent was obtained from all subjects involved in the study.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>The data presented in this study are available on request from the corresponding author.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>Authors Anna Farka&#353;ov&#225; and Luk&#225;&#353; Plank were employed by the company Martin&#8217;s Biopsy Center, Ltd. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></notes><ref-list><title>References</title><ref id="B1-ijms-25-08168"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hendriks</surname><given-names>L.E.</given-names></name><name name-style="western"><surname>Kerr</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>Menis</surname><given-names>J.</given-names></name><name name-style="western"><surname>Mok</surname><given-names>T.S.</given-names></name><name name-style="western"><surname>Nestle</surname><given-names>U.</given-names></name><name name-style="western"><surname>Passaro</surname><given-names>A.</given-names></name><name name-style="western"><surname>Peters</surname><given-names>S.</given-names></name><name name-style="western"><surname>Planchard</surname><given-names>D.</given-names></name><name name-style="western"><surname>Smit</surname><given-names>E.F.</given-names></name><name name-style="western"><surname>Solomon</surname><given-names>B.J.</given-names></name><etal/></person-group><article-title>Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up</article-title><source>Ann. Oncol.</source><year>2023</year><volume>34</volume><fpage>339</fpage><lpage>357</lpage><pub-id pub-id-type="doi">10.1016/j.annonc.2022.12.009</pub-id><pub-id pub-id-type="pmid">36872130</pub-id></element-citation></ref><ref id="B2-ijms-25-08168"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thai</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Solomon</surname><given-names>B.J.</given-names></name><name name-style="western"><surname>Sequist</surname><given-names>L.V.</given-names></name><name name-style="western"><surname>Gainor</surname><given-names>J.F.</given-names></name><name name-style="western"><surname>Heist</surname><given-names>R.S.</given-names></name></person-group><article-title>Lung cancer</article-title><source>Lancet</source><year>2021</year><volume>398</volume><fpage>535</fpage><lpage>554</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(21)00312-3</pub-id><pub-id pub-id-type="pmid">34273294</pub-id></element-citation></ref><ref id="B3-ijms-25-08168"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Morris</surname><given-names>S.W.</given-names></name><name name-style="western"><surname>Kirstein</surname><given-names>M.N.</given-names></name><name name-style="western"><surname>Valentine</surname><given-names>M.B.</given-names></name><name name-style="western"><surname>Dittmer</surname><given-names>K.G.</given-names></name><name name-style="western"><surname>Shapiro</surname><given-names>D.N.</given-names></name><name name-style="western"><surname>Saltman</surname><given-names>D.L.</given-names></name><name name-style="western"><surname>Look</surname><given-names>A.T.</given-names></name></person-group><article-title>Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin&#8217;s lymphoma</article-title><source>Science</source><year>1994</year><volume>263</volume><fpage>1281</fpage><lpage>1284</lpage><pub-id pub-id-type="doi">10.1126/science.8122112</pub-id><pub-id pub-id-type="pmid">8122112</pub-id></element-citation></ref><ref id="B4-ijms-25-08168"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ou</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Bartlett</surname><given-names>C.H.</given-names></name><name name-style="western"><surname>Mino-Kenudson</surname><given-names>M.</given-names></name><name name-style="western"><surname>Cui</surname><given-names>J.</given-names></name><name name-style="western"><surname>Iafrate</surname><given-names>A.J.</given-names></name></person-group><article-title>Crizotinib for the treatment of ALK-rearranged non-small cell lung cancer: A success story to usher in the second decade of molecular targeted therapy in oncology</article-title><source>Oncologist</source><year>2012</year><volume>17</volume><fpage>1351</fpage><lpage>1375</lpage><pub-id pub-id-type="doi">10.1634/theoncologist.2012-0311</pub-id><pub-id pub-id-type="pmid">22989574</pub-id><pub-id pub-id-type="pmcid">PMC3500356</pub-id></element-citation></ref><ref id="B5-ijms-25-08168"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Millett</surname><given-names>R.L.</given-names></name><name name-style="western"><surname>Elkon</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Tabbara</surname><given-names>I.A.</given-names></name></person-group><article-title>Directed therapies in anaplastic lymphoma kinase-rearranged non-small cell lung cancer</article-title><source>Anticancer Res.</source><year>2018</year><volume>38</volume><fpage>4969</fpage><lpage>4975</lpage><pub-id pub-id-type="doi">10.21873/anticanres.12815</pub-id><pub-id pub-id-type="pmid">30194140</pub-id></element-citation></ref><ref id="B6-ijms-25-08168"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kwak</surname><given-names>E.L.</given-names></name><name name-style="western"><surname>Bang</surname><given-names>Y.J.</given-names></name><name name-style="western"><surname>Camidge</surname><given-names>D.R.</given-names></name><name name-style="western"><surname>Shaw</surname><given-names>A.T.</given-names></name><name name-style="western"><surname>Solomon</surname><given-names>B.</given-names></name><name name-style="western"><surname>Maki</surname><given-names>R.G.</given-names></name><name name-style="western"><surname>Ou</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Dezube</surname><given-names>B.J.</given-names></name><name name-style="western"><surname>J&#228;nne</surname><given-names>P.A.</given-names></name><name name-style="western"><surname>Costa</surname><given-names>D.B.</given-names></name><etal/></person-group><article-title>Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer</article-title><source>N. Engl. J. Med.</source><year>2010</year><volume>363</volume><fpage>1693</fpage><lpage>1703</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1006448</pub-id><pub-id pub-id-type="pmid">20979469</pub-id><pub-id pub-id-type="pmcid">PMC3014291</pub-id></element-citation></ref><ref id="B7-ijms-25-08168"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Camidge</surname><given-names>D.R.</given-names></name><name name-style="western"><surname>Bang</surname><given-names>Y.J.</given-names></name><name name-style="western"><surname>Kwak</surname><given-names>E.L.</given-names></name><name name-style="western"><surname>Iafrate</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Varella-Garcia</surname><given-names>M.</given-names></name><name name-style="western"><surname>Fox</surname><given-names>S.B.</given-names></name><name name-style="western"><surname>Riely</surname><given-names>G.J.</given-names></name><name name-style="western"><surname>Solomon</surname><given-names>B.</given-names></name><name name-style="western"><surname>Ou</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>D.W.</given-names></name><etal/></person-group><article-title>Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: Updated results from a phase 1 study</article-title><source>Lancet Oncol.</source><year>2012</year><volume>13</volume><fpage>1011</fpage><lpage>1019</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(12)70344-3</pub-id><pub-id pub-id-type="pmid">22954507</pub-id><pub-id pub-id-type="pmcid">PMC3936578</pub-id></element-citation></ref><ref id="B8-ijms-25-08168"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shaw</surname><given-names>A.T.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>D.W.</given-names></name><name name-style="western"><surname>Mehra</surname><given-names>R.</given-names></name><name name-style="western"><surname>Tan</surname><given-names>D.S.</given-names></name><name name-style="western"><surname>Felip</surname><given-names>E.</given-names></name><name name-style="western"><surname>Chow</surname><given-names>L.Q.</given-names></name><name name-style="western"><surname>Camidge</surname><given-names>D.R.</given-names></name><name name-style="western"><surname>Vansteenkiste</surname><given-names>J.</given-names></name><name name-style="western"><surname>Sharma</surname><given-names>S.</given-names></name><name name-style="western"><surname>De Pas</surname><given-names>T.</given-names></name><etal/></person-group><article-title>Ceritinib in ALK-rearranged non-small-cell lung cancer</article-title><source>N. Engl. J. Med.</source><year>2014</year><volume>370</volume><fpage>1189</fpage><lpage>1197</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1311107</pub-id><pub-id pub-id-type="pmid">24670165</pub-id><pub-id pub-id-type="pmcid">PMC4079055</pub-id></element-citation></ref><ref id="B9-ijms-25-08168"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Peters</surname><given-names>S.</given-names></name><name name-style="western"><surname>Camidge</surname><given-names>D.R.</given-names></name><name name-style="western"><surname>Shaw</surname><given-names>A.T.</given-names></name><name name-style="western"><surname>Gadgeel</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ahn</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>D.W.</given-names></name><name name-style="western"><surname>Ou</surname><given-names>S.I.</given-names></name><name name-style="western"><surname>P&#233;rol</surname><given-names>M.</given-names></name><name name-style="western"><surname>Dziadziuszko</surname><given-names>R.</given-names></name><name name-style="western"><surname>Rosell</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer</article-title><source>N. Engl. J. Med.</source><year>2017</year><volume>9</volume><fpage>829</fpage><lpage>838</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1704795</pub-id><pub-id pub-id-type="pmid">28586279</pub-id></element-citation></ref><ref id="B10-ijms-25-08168"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gettinger</surname><given-names>S.N.</given-names></name><name name-style="western"><surname>Bazhenova</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Langer</surname><given-names>C.J.</given-names></name><name name-style="western"><surname>Salgia</surname><given-names>R.</given-names></name><name name-style="western"><surname>Gold</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Rosell</surname><given-names>R.</given-names></name><name name-style="western"><surname>Shaw</surname><given-names>A.T.</given-names></name><name name-style="western"><surname>Weiss</surname><given-names>G.J.</given-names></name><name name-style="western"><surname>Tugnait</surname><given-names>M.</given-names></name><name name-style="western"><surname>Narasimhan</surname><given-names>N.I.</given-names></name><etal/></person-group><article-title>Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: A single-arm, open-label, phase 1/2 trial</article-title><source>Lancet Oncol.</source><year>2016</year><volume>12</volume><fpage>1683</fpage><lpage>1696</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(16)30392-8</pub-id><pub-id pub-id-type="pmid">27836716</pub-id></element-citation></ref><ref id="B11-ijms-25-08168"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Horn</surname><given-names>L.</given-names></name><name name-style="western"><surname>Infante</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Blumenschein</surname><given-names>G.R.</given-names></name><name name-style="western"><surname>Wakelee</surname><given-names>H.A.</given-names></name><name name-style="western"><surname>Arkenau</surname><given-names>H.</given-names></name><name name-style="western"><surname>Dukart</surname><given-names>G.</given-names></name><name name-style="western"><surname>Liang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Harrow</surname><given-names>K.</given-names></name><name name-style="western"><surname>Gibbons</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lovly</surname><given-names>C.M.</given-names></name><etal/></person-group><article-title>A phase I trial of X-396, a novel ALK inhibitor, in patients with advanced solid tumors</article-title><source>J. Clin. Oncol.</source><year>2014</year><volume>32</volume><fpage>8030</fpage><pub-id pub-id-type="doi">10.1200/jco.2014.32.15_suppl.8030</pub-id></element-citation></ref><ref id="B12-ijms-25-08168"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Camidge</surname><given-names>D.R.</given-names></name><name name-style="western"><surname>Kono</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Flacco</surname><given-names>A.</given-names></name><name name-style="western"><surname>Tan</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Doebele</surname><given-names>R.C.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Crino</surname><given-names>L.</given-names></name><name name-style="western"><surname>Franklin</surname><given-names>W.A.</given-names></name><name name-style="western"><surname>Varella-Garcia</surname><given-names>M.</given-names></name></person-group><article-title>Optimizing the detection of lung cancer patients harboring anaplastic lymphoma kinase (ALK) gene rearrangements potentially suitable for ALK inhibitor treatment</article-title><source>Clin. Cancer Res.</source><year>2010</year><volume>16</volume><fpage>5581</fpage><lpage>5590</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-10-0851</pub-id><pub-id pub-id-type="pmid">21062932</pub-id><pub-id pub-id-type="pmcid">PMC3395226</pub-id></element-citation></ref><ref id="B13-ijms-25-08168"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Paez</surname><given-names>J.G.</given-names></name><name name-style="western"><surname>J&#228;nne</surname><given-names>P.A.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Tracy</surname><given-names>S.</given-names></name><name name-style="western"><surname>Greulich</surname><given-names>H.</given-names></name><name name-style="western"><surname>Gabriel</surname><given-names>S.</given-names></name><name name-style="western"><surname>Herman</surname><given-names>P.</given-names></name><name name-style="western"><surname>Kaye</surname><given-names>F.J.</given-names></name><name name-style="western"><surname>Lindeman</surname><given-names>N.</given-names></name><name name-style="western"><surname>Boggon</surname><given-names>T.J.</given-names></name><etal/></person-group><article-title>EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy</article-title><source>Science</source><year>2004</year><volume>304</volume><fpage>1497</fpage><lpage>1500</lpage><pub-id pub-id-type="doi">10.1126/science.1099314</pub-id><pub-id pub-id-type="pmid">15118125</pub-id></element-citation></ref><ref id="B14-ijms-25-08168"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rekhtman</surname><given-names>N.</given-names></name><name name-style="western"><surname>Leighl</surname><given-names>N.B.</given-names></name><name name-style="western"><surname>Somerfield</surname><given-names>M.R.</given-names></name></person-group><article-title>Molecular testing for selection of patients with lung cancer for epidermal growth factor receptor and anaplastic lymphoma kinase tyrosine kinase inhibitors: American society of clinical oncology endorsement of the college of american pathologists/international association for the study of lung cancer/association for molecular pathology guideline</article-title><source>J. Oncol. Pract.</source><year>2015</year><volume>2</volume><fpage>135</fpage><lpage>136</lpage><pub-id pub-id-type="doi">10.1200/JOP.2014.002303</pub-id><pub-id pub-id-type="pmid">25515718</pub-id></element-citation></ref><ref id="B15-ijms-25-08168"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wynes</surname><given-names>M.W.</given-names></name><name name-style="western"><surname>Sholl</surname><given-names>L.M.</given-names></name><name name-style="western"><surname>Dietel</surname><given-names>M.</given-names></name><name name-style="western"><surname>Schuuring</surname><given-names>E.</given-names></name><name name-style="western"><surname>Tsao</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Yatabe</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Tubbs</surname><given-names>R.R.</given-names></name><name name-style="western"><surname>Hirsch</surname><given-names>F.R.</given-names></name></person-group><article-title>An international interpretation study using the ALK IHC antibody D5F3 and a sensitive detection kit demonstrates high concordance between ALK IHC and ALK and between evaluators</article-title><source>J. Thorac. Oncol.</source><year>2014</year><volume>9</volume><fpage>631</fpage><lpage>638</lpage><pub-id pub-id-type="doi">10.1097/JTO.0000000000000115</pub-id><pub-id pub-id-type="pmid">24722153</pub-id><pub-id pub-id-type="pmcid">PMC4186652</pub-id></element-citation></ref><ref id="B16-ijms-25-08168"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cabillic</surname><given-names>F.</given-names></name><name name-style="western"><surname>Gros</surname><given-names>A.</given-names></name><name name-style="western"><surname>Dugay</surname><given-names>F.</given-names></name><name name-style="western"><surname>Begueret</surname><given-names>H.</given-names></name><name name-style="western"><surname>Mesturoux</surname><given-names>L.</given-names></name><name name-style="western"><surname>Chiforeanu</surname><given-names>D.C.</given-names></name><name name-style="western"><surname>Dufrenot</surname><given-names>L.</given-names></name><name name-style="western"><surname>Jauffret</surname><given-names>V.</given-names></name><name name-style="western"><surname>Dachary</surname><given-names>D.</given-names></name><name name-style="western"><surname>Corre</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Parallel FISH and immunohistochemical studies of ALK status in 3244 non-small-cell lung cancers reveal major discordances</article-title><source>J. Thorac. Oncol.</source><year>2014</year><volume>3</volume><fpage>295</fpage><lpage>306</lpage><pub-id pub-id-type="doi">10.1097/JTO.0000000000000072</pub-id><pub-id pub-id-type="pmid">24518086</pub-id></element-citation></ref><ref id="B17-ijms-25-08168"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ali</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Ou</surname><given-names>S.I.</given-names></name><name name-style="western"><surname>He</surname><given-names>J.</given-names></name><name name-style="western"><surname>Peled</surname><given-names>N.</given-names></name><name name-style="western"><surname>Chmielecki</surname><given-names>J.</given-names></name><name name-style="western"><surname>Pinder</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Palma</surname><given-names>N.A.</given-names></name><name name-style="western"><surname>Akerley</surname><given-names>W.L.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>K.</given-names></name><name name-style="western"><surname>Molina</surname><given-names>J.R.</given-names></name><etal/></person-group><article-title>Identifying ALK rearrangements that are not detected by FISH with targeted next-generation sequencing of lung carcinoma</article-title><source>J. Clin. Oncol.</source><year>2014</year><volume>32</volume><fpage>8049a</fpage><pub-id pub-id-type="doi">10.1200/jco.2014.32.15_suppl.8049</pub-id></element-citation></ref><ref id="B18-ijms-25-08168"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lin</surname><given-names>C.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>X.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>J.</given-names></name><name name-style="western"><surname>He</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Jin</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>X.</given-names></name></person-group><article-title>Comparison of ALK detection by FISH, IHC and NGS to predict benefit from crizotinib in advanced non-small cell lung cancer</article-title><source>Lung Cancer</source><year>2019</year><volume>131</volume><fpage>62</fpage><lpage>68</lpage><pub-id pub-id-type="doi">10.1016/j.lungcan.2019.03.018</pub-id><pub-id pub-id-type="pmid">31027700</pub-id></element-citation></ref><ref id="B19-ijms-25-08168"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Savic</surname><given-names>S.</given-names></name><name name-style="western"><surname>Diebold</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zimmermann</surname><given-names>A.K.</given-names></name><name name-style="western"><surname>Jochum</surname><given-names>W.</given-names></name><name name-style="western"><surname>Baschiera</surname><given-names>B.</given-names></name><name name-style="western"><surname>Grieshaber</surname><given-names>S.</given-names></name><name name-style="western"><surname>Tornillo</surname><given-names>L.</given-names></name><name name-style="western"><surname>Bisig</surname><given-names>B.</given-names></name><name name-style="western"><surname>Kerr</surname><given-names>K.</given-names></name><name name-style="western"><surname>Bubendorf</surname><given-names>L.</given-names></name></person-group><article-title>Screening for ALK in non-small cell lung carcinomas: 5A4 and D5F3 antibodies perform equally well, but combined use with FISH is recommended</article-title><source>Lung Cancer</source><year>2015</year><volume>2</volume><fpage>104</fpage><lpage>109</lpage><pub-id pub-id-type="doi">10.1016/j.lungcan.2015.05.012</pub-id><pub-id pub-id-type="pmid">26056079</pub-id></element-citation></ref><ref id="B20-ijms-25-08168"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sholl</surname><given-names>L.M.</given-names></name><name name-style="western"><surname>Weremowicz</surname><given-names>S.</given-names></name><name name-style="western"><surname>Gray</surname><given-names>S.W.</given-names></name><name name-style="western"><surname>Wong</surname><given-names>K.K.</given-names></name><name name-style="western"><surname>Chirieac</surname><given-names>L.R.</given-names></name><name name-style="western"><surname>Lindeman</surname><given-names>N.I.</given-names></name><name name-style="western"><surname>Hornick</surname><given-names>J.L.</given-names></name></person-group><article-title>Combined use of ALK immunohistochemistry and FISH for optimal detection of ALK-rearranged lung adenocarcinomas</article-title><source>J. Thorac. Oncol.</source><year>2013</year><volume>3</volume><fpage>322</fpage><lpage>328</lpage><pub-id pub-id-type="doi">10.1097/JTO.0b013e31827db604</pub-id><pub-id pub-id-type="pmcid">PMC3573350</pub-id><pub-id pub-id-type="pmid">23407557</pub-id></element-citation></ref><ref id="B21-ijms-25-08168"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Choi</surname><given-names>Y.L.</given-names></name><name name-style="western"><surname>Won</surname><given-names>J.K.</given-names></name><name name-style="western"><surname>Hirsch</surname><given-names>F.R.</given-names></name><name name-style="western"><surname>Ahn</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Ahn</surname><given-names>M.</given-names></name><name name-style="western"><surname>Park</surname><given-names>K.</given-names></name></person-group><article-title>A dramatic response to crizotinib in a non-small-cell lung cancer patient with IHC-positive and FISH-negative ALK</article-title><source>J. Thorac. Oncol.</source><year>2012</year><volume>7</volume><fpage>e36</fpage><lpage>e38</lpage><pub-id pub-id-type="doi">10.1097/JTO.0b013e318274694e</pub-id><pub-id pub-id-type="pmid">23154564</pub-id></element-citation></ref><ref id="B22-ijms-25-08168"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Peled</surname><given-names>N.</given-names></name><name name-style="western"><surname>Palmer</surname><given-names>G.</given-names></name><name name-style="western"><surname>Hirsch</surname><given-names>F.R.</given-names></name><name name-style="western"><surname>Wynes</surname><given-names>M.W.</given-names></name><name name-style="western"><surname>Ilouze</surname><given-names>M.</given-names></name><name name-style="western"><surname>Varella-Garcia</surname><given-names>M.</given-names></name><name name-style="western"><surname>Soussan-Gutman</surname><given-names>L.</given-names></name><name name-style="western"><surname>Otto</surname><given-names>G.A.</given-names></name><name name-style="western"><surname>Stephens</surname><given-names>P.J.</given-names></name><name name-style="western"><surname>Ross</surname><given-names>J.S.</given-names></name><etal/></person-group><article-title>Next-generation sequencing identifies and immunohistochemistry confirms a novel crizotinib-sensitive ALK rearrangement in a patient with metastatic non-small-cell lung cancer</article-title><source>J. Thorac. Oncol.</source><year>2012</year><volume>7</volume><fpage>e14</fpage><lpage>e16</lpage><pub-id pub-id-type="doi">10.1097/JTO.0b013e3182614ab5</pub-id><pub-id pub-id-type="pmid">22895149</pub-id><pub-id pub-id-type="pmcid">PMC3645938</pub-id></element-citation></ref><ref id="B23-ijms-25-08168"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Van der Wekken</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Pelgrim</surname><given-names>R.</given-names></name><name name-style="western"><surname>Hart</surname><given-names>N.</given-names></name><name name-style="western"><surname>Werner</surname><given-names>N.</given-names></name><name name-style="western"><surname>Mastik</surname><given-names>M.F.</given-names></name><name name-style="western"><surname>Hendriks</surname><given-names>L.</given-names></name><name name-style="western"><surname>van der Heijden</surname><given-names>E.H.F.M.</given-names></name><name name-style="western"><surname>Looijen-Salamon</surname><given-names>M.</given-names></name><name name-style="western"><surname>de Langen</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Staal-van den Brekel</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Dichotomous ALK-IHC Is a Better Predictor for ALK Inhibition Outcome than Traditional ALK-FISH in Advanced Non-Small Cell Lung Cancer</article-title><source>Clin. Cancer Res.</source><year>2017</year><volume>23</volume><fpage>4251</fpage><lpage>4258</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-16-1631</pub-id><pub-id pub-id-type="pmid">28183714</pub-id></element-citation></ref><ref id="B24-ijms-25-08168"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cabillic</surname><given-names>F.</given-names></name><name name-style="western"><surname>Hofman</surname><given-names>P.</given-names></name><name name-style="western"><surname>Ilie</surname><given-names>M.</given-names></name><name name-style="western"><surname>Peled</surname><given-names>N.</given-names></name><name name-style="western"><surname>Hochmair</surname><given-names>M.</given-names></name><name name-style="western"><surname>Dietel</surname><given-names>M.</given-names></name><name name-style="western"><surname>Von Laffert</surname><given-names>M.</given-names></name><name name-style="western"><surname>Gosney</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Lopez-Rios</surname><given-names>F.</given-names></name><name name-style="western"><surname>Erb</surname><given-names>G.</given-names></name><etal/></person-group><article-title>ALK IHC and FISH discordant results in patients with NSCLC and treatment response: For discussion of the question-to treat or not to treat?</article-title><source>ESMO Open</source><year>2018</year><volume>3</volume><fpage>e000419</fpage><pub-id pub-id-type="doi">10.1136/esmoopen-2018-000419</pub-id><pub-id pub-id-type="pmid">30245863</pub-id><pub-id pub-id-type="pmcid">PMC6144904</pub-id></element-citation></ref><ref id="B25-ijms-25-08168"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Scattone</surname><given-names>A.</given-names></name><name name-style="western"><surname>Catino</surname><given-names>A.</given-names></name><name name-style="western"><surname>Schirosi</surname><given-names>L.</given-names></name><name name-style="western"><surname>Caldarola</surname><given-names>L.</given-names></name><name name-style="western"><surname>Tommasi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lacalamita</surname><given-names>R.</given-names></name><name name-style="western"><surname>Montagna</surname><given-names>E.S.</given-names></name><name name-style="western"><surname>Galetta</surname><given-names>D.</given-names></name><name name-style="western"><surname>Serio</surname><given-names>G.</given-names></name><name name-style="western"><surname>Zito</surname><given-names>F.A.</given-names></name><etal/></person-group><article-title>Discordance between FISH, IHC, and NGS Analysis of ALK Status in Advanced Non-Small Cell Lung Cancer (NSCLC): A Brief Report of 7 Cases</article-title><source>Transl. Oncol.</source><year>2019</year><volume>12</volume><fpage>389</fpage><lpage>395</lpage><pub-id pub-id-type="doi">10.1016/j.tranon.2018.11.006</pub-id><pub-id pub-id-type="pmid">30529852</pub-id><pub-id pub-id-type="pmcid">PMC6280637</pub-id></element-citation></ref><ref id="B26-ijms-25-08168"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thunnissen</surname><given-names>E.</given-names></name><name name-style="western"><surname>Lissenberg-Witte</surname><given-names>B.I.</given-names></name><name name-style="western"><surname>van den Heuvel</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Monkhorst</surname><given-names>K.</given-names></name><name name-style="western"><surname>Skov</surname><given-names>B.G.</given-names></name><name name-style="western"><surname>S&#248;rensen</surname><given-names>J.B.</given-names></name><name name-style="western"><surname>Mellemgaard</surname><given-names>A.</given-names></name><name name-style="western"><surname>Dingemans</surname><given-names>A.M.C.</given-names></name><name name-style="western"><surname>Speel</surname><given-names>E.J.M.</given-names></name><name name-style="western"><surname>de Langen</surname><given-names>A.J.</given-names></name><etal/></person-group><article-title>ALK immunohistochemistry positive, FISH negative NSCLC is infrequent, but associated with impaired survival following treatment with crizotinib</article-title><source>Lung Cancer</source><year>2019</year><volume>138</volume><fpage>13</fpage><lpage>18</lpage><pub-id pub-id-type="doi">10.1016/j.lungcan.2019.09.023</pub-id><pub-id pub-id-type="pmid">31630043</pub-id></element-citation></ref><ref id="B27-ijms-25-08168"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gao</surname><given-names>X.</given-names></name><name name-style="western"><surname>Sholl</surname><given-names>L.M.</given-names></name><name name-style="western"><surname>Nishino</surname><given-names>M.</given-names></name><name name-style="western"><surname>Heng</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>J&#228;nne</surname><given-names>P.A.</given-names></name><name name-style="western"><surname>Oxnard</surname><given-names>G.R.</given-names></name></person-group><article-title>Clinical Implications of Variant ALK FISH Rearrangement Patterns</article-title><source>J. Thorac. Oncol.</source><year>2015</year><volume>11</volume><fpage>1648</fpage><lpage>1652</lpage><pub-id pub-id-type="doi">10.1097/JTO.0000000000000665</pub-id><pub-id pub-id-type="pmid">26536196</pub-id><pub-id pub-id-type="pmcid">PMC4634010</pub-id></element-citation></ref><ref id="B28-ijms-25-08168"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Clav&#233;</surname><given-names>S.</given-names></name><name name-style="western"><surname>Rodon</surname><given-names>N.</given-names></name><name name-style="western"><surname>Pijuan</surname><given-names>L.</given-names></name><name name-style="western"><surname>D&#237;az</surname><given-names>O.</given-names></name><name name-style="western"><surname>Lorenzo</surname><given-names>M.</given-names></name><name name-style="western"><surname>Rocha</surname><given-names>P.</given-names></name><name name-style="western"><surname>Taus</surname><given-names>&#193;.</given-names></name><name name-style="western"><surname>Blanco</surname><given-names>R.</given-names></name><name name-style="western"><surname>Bosch-Barrera</surname><given-names>J.</given-names></name><name name-style="western"><surname>Reguart</surname><given-names>N.</given-names></name><etal/></person-group><article-title>Next-generation Sequencing for ALK and ROS1 Rearrangement Detection in Patients With Non-small-cell Lung Cancer: Implications of FISH-positive Patterns</article-title><source>Clin. Lung Cancer</source><year>2019</year><volume>20</volume><fpage>e421</fpage><lpage>e429</lpage><pub-id pub-id-type="doi">10.1016/j.cllc.2019.02.008</pub-id><pub-id pub-id-type="pmid">30898567</pub-id></element-citation></ref><ref id="B29-ijms-25-08168"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dacic</surname><given-names>S.</given-names></name><name name-style="western"><surname>Villaruz</surname><given-names>L.C.</given-names></name><name name-style="western"><surname>Abberbock</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mahaffey</surname><given-names>A.</given-names></name><name name-style="western"><surname>Incharoen</surname><given-names>P.</given-names></name><name name-style="western"><surname>Nikiforova</surname><given-names>M.N.</given-names></name></person-group><article-title>ALK FISH patterns and the detection of ALK fusions by next generation sequencing in lung adenocarcinoma</article-title><source>Oncotarget</source><year>2016</year><volume>7</volume><fpage>82943</fpage><lpage>82952</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.12705</pub-id><pub-id pub-id-type="pmid">27769042</pub-id><pub-id pub-id-type="pmcid">PMC5347743</pub-id></element-citation></ref><ref id="B30-ijms-25-08168"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zito Marino</surname><given-names>F.</given-names></name><name name-style="western"><surname>Botti</surname><given-names>G.</given-names></name><name name-style="western"><surname>Aquino</surname><given-names>G.</given-names></name><name name-style="western"><surname>Ferrero</surname><given-names>S.</given-names></name><name name-style="western"><surname>Gaudioso</surname><given-names>G.</given-names></name><name name-style="western"><surname>Palleschi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Rocco</surname><given-names>D.</given-names></name><name name-style="western"><surname>Salvi</surname><given-names>R.</given-names></name><name name-style="western"><surname>Micheli</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Micheli</surname><given-names>P.</given-names></name><etal/></person-group><article-title>Unproductive Effects of ALK Gene Amplification and Copy Number Gain in Non-Small-Cell Lung Cancer. ALK Gene Amplification and Copy Gain in NSCLC</article-title><source>Int. J. Mol. Sci.</source><year>2020</year><volume>21</volume><elocation-id>4927</elocation-id><pub-id pub-id-type="doi">10.3390/ijms21144927</pub-id><pub-id pub-id-type="pmid">32664698</pub-id><pub-id pub-id-type="pmcid">PMC7404032</pub-id></element-citation></ref><ref id="B31-ijms-25-08168"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Peretti</surname><given-names>U.</given-names></name><name name-style="western"><surname>Ferrara</surname><given-names>R.</given-names></name><name name-style="western"><surname>Pilotto</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kinspergher</surname><given-names>S.</given-names></name><name name-style="western"><surname>Caccese</surname><given-names>M.</given-names></name><name name-style="western"><surname>Santo</surname><given-names>A.</given-names></name><name name-style="western"><surname>Brunelli</surname><given-names>M.</given-names></name><name name-style="western"><surname>Cali&#242;</surname><given-names>A.</given-names></name><name name-style="western"><surname>Carbognin</surname><given-names>L.</given-names></name><name name-style="western"><surname>Sperduti</surname><given-names>I.</given-names></name><etal/></person-group><article-title>ALK gene copy number gains in non-small-cell lung cancer: Prognostic impact and clinico-pathological correlations</article-title><source>Respir. Res.</source><year>2016</year><volume>17</volume><fpage>105</fpage><pub-id pub-id-type="doi">10.1186/s12931-016-0422-8</pub-id><pub-id pub-id-type="pmid">27561692</pub-id><pub-id pub-id-type="pmcid">PMC5000438</pub-id></element-citation></ref><ref id="B32-ijms-25-08168"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Salido</surname><given-names>M.</given-names></name><name name-style="western"><surname>Pijuan</surname><given-names>L.</given-names></name><name name-style="western"><surname>Mart&#237;nez-Avil&#233;s</surname><given-names>L.</given-names></name><name name-style="western"><surname>Galv&#225;n</surname><given-names>A.B.</given-names></name><name name-style="western"><surname>Ca&#241;adas</surname><given-names>I.</given-names></name><name name-style="western"><surname>Rovira</surname><given-names>A.</given-names></name><name name-style="western"><surname>Zanui</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mart&#237;nez</surname><given-names>A.</given-names></name><name name-style="western"><surname>Longar&#243;n</surname><given-names>R.</given-names></name><name name-style="western"><surname>Sole</surname><given-names>F.</given-names></name><etal/></person-group><article-title>Increased ALK gene copy number and amplification are frequent in non-small cell lung cancer</article-title><source>J. Thorac. Oncol.</source><year>2011</year><volume>6</volume><fpage>21</fpage><lpage>27</lpage><pub-id pub-id-type="doi">10.1097/JTO.0b013e3181fb7cd6</pub-id><pub-id pub-id-type="pmid">21107285</pub-id><pub-id pub-id-type="pmcid">PMC3359090</pub-id></element-citation></ref><ref id="B33-ijms-25-08168"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Katayama</surname><given-names>R.</given-names></name><name name-style="western"><surname>Khan</surname><given-names>T.M.</given-names></name><name name-style="western"><surname>Benes</surname><given-names>C.</given-names></name><name name-style="western"><surname>Lifshits</surname><given-names>E.</given-names></name><name name-style="western"><surname>Ebi</surname><given-names>H.</given-names></name><name name-style="western"><surname>Rivera</surname><given-names>V.M.</given-names></name><name name-style="western"><surname>Shakespeare</surname><given-names>W.C.</given-names></name><name name-style="western"><surname>Iafrate</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Engelman</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Shaw</surname><given-names>A.T.</given-names></name></person-group><article-title>Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2011</year><volume>108</volume><fpage>7535</fpage><lpage>7540</lpage><pub-id pub-id-type="doi">10.1073/pnas.1019559108</pub-id><pub-id pub-id-type="pmid">21502504</pub-id><pub-id pub-id-type="pmcid">PMC3088626</pub-id></element-citation></ref><ref id="B34-ijms-25-08168"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Katayama</surname><given-names>R.</given-names></name><name name-style="western"><surname>Shaw</surname><given-names>A.T.</given-names></name><name name-style="western"><surname>Khan</surname><given-names>T.M.</given-names></name><name name-style="western"><surname>Mino-Kenudson</surname><given-names>M.</given-names></name><name name-style="western"><surname>Solomon</surname><given-names>B.J.</given-names></name><name name-style="western"><surname>Halmos</surname><given-names>B.</given-names></name><name name-style="western"><surname>Jessop</surname><given-names>N.A.</given-names></name><name name-style="western"><surname>Wain</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Yeo</surname><given-names>A.T.</given-names></name><name name-style="western"><surname>Benes</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers</article-title><source>Sci. Transl. Med.</source><year>2012</year><volume>4</volume><fpage>120ra17</fpage><pub-id pub-id-type="doi">10.1126/scitranslmed.3003316</pub-id><pub-id pub-id-type="pmid">22277784</pub-id><pub-id pub-id-type="pmcid">PMC3385512</pub-id></element-citation></ref><ref id="B35-ijms-25-08168"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thunnissen</surname><given-names>E.</given-names></name><name name-style="western"><surname>Bubendorf</surname><given-names>L.</given-names></name><name name-style="western"><surname>Dietel</surname><given-names>M.</given-names></name><name name-style="western"><surname>Elmberger</surname><given-names>G.</given-names></name><name name-style="western"><surname>Kerr</surname><given-names>K.</given-names></name><name name-style="western"><surname>Lopez-Rios</surname><given-names>F.</given-names></name><name name-style="western"><surname>Moch</surname><given-names>H.</given-names></name><name name-style="western"><surname>Olszewski</surname><given-names>W.</given-names></name><name name-style="western"><surname>Pauwels</surname><given-names>P.</given-names></name><name name-style="western"><surname>Penault-Llorca</surname><given-names>F.</given-names></name><etal/></person-group><article-title>EML4-ALK testing in non-small cell carcinomas of the lung: A review with recommendations</article-title><source>Virchows Arch.</source><year>2012</year><volume>461</volume><fpage>245</fpage><lpage>257</lpage><pub-id pub-id-type="doi">10.1007/s00428-012-1281-4</pub-id><pub-id pub-id-type="pmid">22825000</pub-id><pub-id pub-id-type="pmcid">PMC3432214</pub-id></element-citation></ref><ref id="B36-ijms-25-08168"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schildhaus</surname><given-names>H.U.</given-names></name><name name-style="western"><surname>Binot</surname><given-names>E.</given-names></name><name name-style="western"><surname>Wolf</surname><given-names>J.</given-names></name></person-group><article-title>Validation of a Simplified Approach to Detect ALK Translocations in Lung Cancer Samples by FISH</article-title><source>Mod. Pathol.</source><year>2016</year><volume>29</volume><fpage>482A</fpage></element-citation></ref><ref id="B37-ijms-25-08168"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Datto</surname><given-names>M.</given-names></name><name name-style="western"><surname>Duncavage</surname><given-names>E.J.</given-names></name><name name-style="western"><surname>Kulkarni</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lindeman</surname><given-names>N.I.</given-names></name><name name-style="western"><surname>Roy</surname><given-names>S.</given-names></name><name name-style="western"><surname>Tsimberidou</surname><given-names>A.M.</given-names></name></person-group><article-title>Standards and guidelines for the interpretation and reporting of sequence variants in cancer: A joint consensus recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists</article-title><source>J. Mol. Diagn.</source><year>2017</year><volume>19</volume><fpage>4</fpage><lpage>23</lpage><pub-id pub-id-type="doi">10.1016/j.jmoldx.2016.10.002</pub-id><pub-id pub-id-type="pmid">27993330</pub-id><pub-id pub-id-type="pmcid">PMC5707196</pub-id></element-citation></ref><ref id="B38-ijms-25-08168"><label>38.</label><element-citation publication-type="webpage"><person-group person-group-type="author"><name name-style="western"><surname>Mayer</surname><given-names>M.</given-names></name></person-group><article-title>Confidence Intervals. R package Version 0.1.2</article-title><year>2022</year><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://CRAN.R-project.org/package=confintr" ext-link-type="uri">https://CRAN.R-project.org/package=confintr</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-02-22">(accessed on 22 February 2024)</date-in-citation></element-citation></ref><ref id="B39-ijms-25-08168"><label>39.</label><element-citation publication-type="webpage"><person-group person-group-type="author"><name name-style="western"><surname>Murdoch</surname><given-names>D.</given-names></name></person-group><article-title>Formula-Driven Table Generation. R Package Version 0.9.22</article-title><year>2023</year><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://dmurdoch.github.io/tables/" ext-link-type="uri">https://dmurdoch.github.io/tables/</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-02-22">(accessed on 22 February 2024)</date-in-citation></element-citation></ref><ref id="B40-ijms-25-08168"><label>40.</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>R Core Team</collab></person-group><source>R: A Language and Environment for Statistical Computing</source><publisher-name>R Foundation for Statistical Computing</publisher-name><publisher-loc>Vienna, Austria</publisher-loc><year>2021</year><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.R-project.org/" ext-link-type="uri">https://www.R-project.org/</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-02-22">(accessed on 22 February 2024)</date-in-citation></element-citation></ref><ref id="B41-ijms-25-08168"><label>41.</label><element-citation publication-type="webpage"><person-group person-group-type="author"><name name-style="western"><surname>Zhu</surname><given-names>H.</given-names></name></person-group><article-title>kableExtra: Construct Complex Table with &#8216;kable&#8217; andPipe Syntax. R Package Version 1.3.4</article-title><year>2021</year><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://CRAN.R-project.org/package=kableExtra" ext-link-type="uri">https://CRAN.R-project.org/package=kableExtra</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-02-22">(accessed on 22 February 2024)</date-in-citation></element-citation></ref></ref-list></back><floats-group><fig position="float" id="ijms-25-08168-f001" orientation="portrait"><label>Figure 1</label><caption><p>(<bold>a</bold>) Pattern combinations identified in positive discordant samples. (<bold>b</bold>) Pattern combinations identified in positive concordant samples.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="ijms-25-08168-g001.jpg"/></fig><fig position="float" id="ijms-25-08168-f002" orientation="portrait"><label>Figure 2</label><caption><p>ZytoLight <sup>&#174;</sup> SPEC ALK/EML4 TriCheck&#8482; Probe Design, reprinted with permission from Schildhaus HU et al. [<xref rid="B36-ijms-25-08168" ref-type="bibr">36</xref>] Signal interpretation guide, 2016. &#169; 2024 ZYTOVISION GmbH.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="ijms-25-08168-g002.jpg"/></fig><fig position="float" id="ijms-25-08168-f003" orientation="portrait"><label>Figure 3</label><caption><p>Classification of FISH patterns in samples analyzed with ALK/EML4 fusion probe.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="ijms-25-08168-g003.jpg"/></fig><table-wrap position="float" id="ijms-25-08168-t001" orientation="portrait"><object-id pub-id-type="pii">ijms-25-08168-t001_Table 1</object-id><label>Table 1</label><caption><p><italic toggle="yes">ALK</italic> rearrangement detection and <italic toggle="yes">ALK</italic> discordance among population groups.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Age</th><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Total</th><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Positive FISH</th><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Negative FISH</th><th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Discordant Cases</th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">FISH&#8722;, IHC+</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">FISH+, IHC&#8722;</th></tr></thead><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">20&#8211;29</td><td align="center" valign="middle" rowspan="1" colspan="1">6</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">4</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">20&#8211;29 men</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">20&#8211;29 women</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">30&#8211;39</td><td align="center" valign="middle" rowspan="1" colspan="1">28</td><td align="center" valign="middle" rowspan="1" colspan="1">9</td><td align="center" valign="middle" rowspan="1" colspan="1">19</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">30&#8211;39 men</td><td align="center" valign="middle" rowspan="1" colspan="1">14</td><td align="center" valign="middle" rowspan="1" colspan="1">4</td><td align="center" valign="middle" rowspan="1" colspan="1">10</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">30&#8211;39 women</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">14</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">40&#8211;49</td><td align="center" valign="middle" rowspan="1" colspan="1">133</td><td align="center" valign="middle" rowspan="1" colspan="1">33</td><td align="center" valign="middle" rowspan="1" colspan="1">100</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">40&#8211;49 men</td><td align="center" valign="middle" rowspan="1" colspan="1">75</td><td align="center" valign="middle" rowspan="1" colspan="1">18</td><td align="center" valign="middle" rowspan="1" colspan="1">57</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">40&#8211;49 women</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">58</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">15</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">43</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">50&#8211;59</td><td align="center" valign="middle" rowspan="1" colspan="1">487</td><td align="center" valign="middle" rowspan="1" colspan="1">55</td><td align="center" valign="middle" rowspan="1" colspan="1">432</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">7</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">50&#8211;59 men</td><td align="center" valign="middle" rowspan="1" colspan="1">296</td><td align="center" valign="middle" rowspan="1" colspan="1">26</td><td align="center" valign="middle" rowspan="1" colspan="1">270</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">6</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">50&#8211;59 women</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">191</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">29</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">162</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">60&#8211;69</td><td align="center" valign="middle" rowspan="1" colspan="1">1170</td><td align="center" valign="middle" rowspan="1" colspan="1">76</td><td align="center" valign="middle" rowspan="1" colspan="1">1094</td><td align="center" valign="middle" rowspan="1" colspan="1">6</td><td align="center" valign="middle" rowspan="1" colspan="1">18</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">60&#8211;69 men</td><td align="center" valign="middle" rowspan="1" colspan="1">737</td><td align="center" valign="middle" rowspan="1" colspan="1">29</td><td align="center" valign="middle" rowspan="1" colspan="1">708</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">10</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">60&#8211;69 women</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">433</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">47</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">386</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">70&#8211;79</td><td align="center" valign="middle" rowspan="1" colspan="1">743</td><td align="center" valign="middle" rowspan="1" colspan="1">41</td><td align="center" valign="middle" rowspan="1" colspan="1">702</td><td align="center" valign="middle" rowspan="1" colspan="1">7</td><td align="center" valign="middle" rowspan="1" colspan="1">6</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">70&#8211;79 men</td><td align="center" valign="middle" rowspan="1" colspan="1">520</td><td align="center" valign="middle" rowspan="1" colspan="1">16</td><td align="center" valign="middle" rowspan="1" colspan="1">504</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">70&#8211;79 women</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">223</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">25</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">198</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">80&#8211;89</td><td align="center" valign="middle" rowspan="1" colspan="1">114</td><td align="center" valign="middle" rowspan="1" colspan="1">6</td><td align="center" valign="middle" rowspan="1" colspan="1">108</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">80&#8211;89 men</td><td align="center" valign="middle" rowspan="1" colspan="1">71</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">69</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">80&#8211;89 women</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">43</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">39</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">90&#8211;99</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">90&#8211;99 men</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">90&#8211;99 women</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">total</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2683</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">222</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2461</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">17</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">33</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">men</td><td align="center" valign="middle" rowspan="1" colspan="1">1716</td><td align="center" valign="middle" rowspan="1" colspan="1">95</td><td align="center" valign="middle" rowspan="1" colspan="1">1621</td><td align="center" valign="middle" rowspan="1" colspan="1">3</td><td align="center" valign="middle" rowspan="1" colspan="1">20</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">women</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">967</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">127</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">840</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">14</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">13</td></tr></tbody></table></table-wrap><table-wrap position="float" id="ijms-25-08168-t002" orientation="portrait"><object-id pub-id-type="pii">ijms-25-08168-t002_Table 2</object-id><label>Table 2</label><caption><p>Histopathological data as provided by sending departments (no second look option).</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Histological Type</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Total (<italic toggle="yes">n</italic> = 239)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Positive Discordant (<italic toggle="yes">n</italic> = 33)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Negative Discordant (<italic toggle="yes">n</italic> = 17)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Positive Concordant (<italic toggle="yes">n</italic> = 189)</th></tr></thead><tbody><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Squamous cell carcinoma</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4 (1.67%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2 (6.06%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2 (11.76%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0 (0.00%)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Minimally invasive adenocarcinoma</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2 (0.83%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1 (3.03%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1 (5.88%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0 (0.00%)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Adenocarcinoma, NOS</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">72 (30.12%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">11 (33.33%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4 (23.53%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">57 (30.16%)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Adenocarcinoma, NOS, mucin not detected</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6 (2.51%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1 (3.03%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0 (0.00%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5 (2.65%)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Adenocarcinoma, NOS, mucin producing</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8 (3.35%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0 (0.00%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0 (0.00%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8 (4.23%)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Lepidic predominant adenocarcinoma</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3 (1.26%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1 (3.03%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0 (0.00%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2 (1.06%)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Acinar predominant adenocarcinoma</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">24 (10.04%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2 (6.06%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1 (5.88%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">21 (11.11%)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Papillary predominant adenocarcinoma</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12 (5.02%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0 (0.00%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1 (5.88%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">11 (5.82%)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Solid predominant adenocarcinoma</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">29 (12.13%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4 (12.12%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4 (23.53%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">21 (11.11%)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Micropapillary predominant adenocarcinoma</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6 (2.51%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0 (0.00%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0 (0.00%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6 (3.17%)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Signet ring cell adenocarcinoma</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4 (1.67%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0 (0.00%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0 (0.00%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4 (2.12%)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mucinous adenocarcinoma</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9 (3.77%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1 (3.03%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0 (0.00%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8 (4.23%)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Clear cell adenocarcinoma</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1 (0.42%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1 (3.03%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0 (0.00%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0 (0.00%)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">G3 adenocarcinoma, growth patterns not specified</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9 (3.77%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3 (9.09%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0 (0.00%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6 (3.17%)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">G2 adenocarcinoma, growth patterns not specified</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1 (0.42%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0 (0.00%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0 (0.00%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1 (0.53%)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pleomorphic carcinoma</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1 (0.42%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1 (3.03%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0 (0.00%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0 (0.00%)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sarcomatoid carcinoma</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1 (0.42%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0 (0.00%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0 (0.00%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1 (0.53%)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Adenosquamous carcinoma</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3 (1.26%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1 (3.03%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0 (0.00%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2 (1.06%)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Combined NEC and adenocarcinoma</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2 (0.83%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1 (3.03%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0 (0.00%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1 (0.53%)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NSCLC, NOS</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3 (1.26%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0 (0.00%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0 (0.00%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3 (1.59%)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Metastatic adenocarcinoma</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">26 (10.88%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3 (9.09%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2 (11.76%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">21 (11.11%)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Data unavailable</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">13 (5.44%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0 (0.00%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2 (11.76%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">11 (5.82%)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Mucin production in one or more components</td><td align="center" valign="middle" rowspan="1" colspan="1">41 (17.01%)</td><td align="center" valign="middle" rowspan="1" colspan="1">2 (6.06%)</td><td align="center" valign="middle" rowspan="1" colspan="1">1 (5.88%)</td><td align="center" valign="middle" rowspan="1" colspan="1">38 (20.10%)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Mucin not detected</td><td align="center" valign="middle" rowspan="1" colspan="1">11 (4.56%)</td><td align="center" valign="middle" rowspan="1" colspan="1">3 (9.09%)</td><td align="center" valign="middle" rowspan="1" colspan="1">2 (11.76%)</td><td align="center" valign="middle" rowspan="1" colspan="1">6 (3.17%)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Not specified</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">187 (77.59%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">28 (84.85%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">14 (82.35%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">145 (76.72%)</td></tr></tbody></table></table-wrap><table-wrap position="float" id="ijms-25-08168-t003" orientation="portrait"><object-id pub-id-type="pii">ijms-25-08168-t003_Table 3</object-id><label>Table 3</label><caption><p>Comparison of <italic toggle="yes">ALK</italic> copy number gains in all discordant vs. positive concordant samples.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Positive Discordant (<italic toggle="yes">n</italic> = 33)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Negative Discordant (<italic toggle="yes">n</italic> = 17)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Positive Concordant<break/>(<italic toggle="yes">n</italic> = 189)</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">3 or less <italic toggle="yes">ALK</italic> CNGs</td><td align="center" valign="middle" rowspan="1" colspan="1">12 (36.36%)</td><td align="center" valign="middle" rowspan="1" colspan="1">11 (64.70%)</td><td align="center" valign="middle" rowspan="1" colspan="1">129 (68.25%)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">4&#8211;6 <italic toggle="yes">ALK</italic> CNGs</td><td align="center" valign="middle" rowspan="1" colspan="1">8 (24.24%)</td><td align="center" valign="middle" rowspan="1" colspan="1">2 (11.76%)</td><td align="center" valign="middle" rowspan="1" colspan="1">40 (21.16%)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">7&#8211;9 <italic toggle="yes">ALK</italic> CNGs</td><td align="center" valign="middle" rowspan="1" colspan="1">6 (18.18%)</td><td align="center" valign="middle" rowspan="1" colspan="1">1 (5.88%)</td><td align="center" valign="middle" rowspan="1" colspan="1">19 (10.05%)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10+ <italic toggle="yes">ALK</italic> CNGs</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7 (21.21%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3 (17.65%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1 (0.53%)</td></tr></tbody></table></table-wrap><table-wrap position="float" id="ijms-25-08168-t004" orientation="portrait"><object-id pub-id-type="pii">ijms-25-08168-t004_Table 4</object-id><label>Table 4</label><caption><p>Pattern distribution in positive concordant and positive discordant samples.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Patterns &lt;15%</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">At Least 1 Pattern &#8805;15%</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Total</th></tr></thead><tbody><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Discordant samples (IHC&#8722;, FISH+)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">13</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">16</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">29</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8195;1 pattern identified</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#8195;&#8195;Inversion</td><td align="center" valign="middle" rowspan="1" colspan="1">5</td><td align="center" valign="middle" rowspan="1" colspan="1">5</td><td align="center" valign="middle" rowspan="1" colspan="1">10</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#8195;&#8195;Interstitial deletion</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#8195;&#8195;Translocation</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8195;&#8195;5&#8242; deletion</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8195;2 patterns identified</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">14</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#8195;&#8195;Interstitial deletion + inversion</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">3</td><td align="center" valign="middle" rowspan="1" colspan="1">3</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#8195;&#8195;5&#8242; deletion + inversion</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#8195;&#8195;5&#8242; deletion + translocation</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">4</td><td align="center" valign="middle" rowspan="1" colspan="1">4</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#8195;&#8195;Interstitial deletion + translocation</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#8195;&#8195;Translocation + inversion</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8195;&#8195;Inversion + translocation</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8195;3 patterns identified</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8195;&#8195;5&#8242; deletion + translocation + inversion</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Concordant samples (IHC+, FISH+)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">166</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">168</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8195;1 pattern identified</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">135</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">137</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#8195;&#8195;Inversion</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">131</td><td align="center" valign="middle" rowspan="1" colspan="1">133</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#8195;&#8195;Interstitial deletion</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">3</td><td align="center" valign="middle" rowspan="1" colspan="1">3</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#8195;&#8195;Translocation</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8195;&#8195;5&#8242; deletion</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8195;2 patterns identified</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">30</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">30</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#8195;&#8195;Interstitial deletion + inversion</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">21</td><td align="center" valign="middle" rowspan="1" colspan="1">21</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#8195;&#8195;5&#8242; deletion + interstitial deletion</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">4</td><td align="center" valign="middle" rowspan="1" colspan="1">4</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#8195;&#8195;Translocation + interstitial deletion</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#8195;&#8195;Interstitial deletion + translocation</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8195;&#8195;Translocation + inversion</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8195;3 patterns identified</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8195;&#8195;5&#8242; deletion + translocation + inversion</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td></tr></tbody></table></table-wrap><table-wrap position="float" id="ijms-25-08168-t005" orientation="portrait"><object-id pub-id-type="pii">ijms-25-08168-t005_Table 5</object-id><label>Table 5</label><caption><p><italic toggle="yes">ALK</italic> discordant and concordant cases analyzed with NGS.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Case No.</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Gender</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Age</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">ALK FISH Pattern</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">ALK Copy Number Gains</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">IHC</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">NGS</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">M</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">69</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">rearranged nuclei: 26%<break/>pattern: translocation + inversion</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">16% 4&#8211;5 copies;<break/>1% 9 copies</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">negative</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IA: no variants reported;<break/>IB: <italic toggle="yes">TP53</italic><break/>p.P190L<break/>c.569C&gt;T</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">M</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">60</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">rearranged nuclei: 68%<break/>pattern: inversion</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">17% 4&#8211;10 copies;<break/>8% &gt;10 copies</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">negative</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IA: no variants reported;<break/>IB: no variants reported</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">M</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">53</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">rearranged nuclei: 64%<break/>pattern: inversion</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">not detected</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">negative</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IA: <italic toggle="yes">EML4, ALK</italic><break/>fusion transcript;<break/>IB: <italic toggle="yes">MYC</italic><break/>copy number gain (3 copies)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">M</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">70</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">rearranged nuclei: 44%<break/>pattern: 5&#8242; deletion + translocation</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">11% 4&#8211;6 copies</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">negative</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IA: no variants reported;<break/>IB: <italic toggle="yes">EGFR</italic><break/>copy number gain (10 copies)<break/><italic toggle="yes">MYC</italic><break/>copy number gain<break/>(3 copies)<break/>TP53<break/>p.I195T<break/>c.584T&gt;C</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">M</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">68</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">rearranged nuclei: 30%<break/>pattern: translocation + interstitial deletion</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">52% 4&#8211;10 copies</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">negative in limited material</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IA: no variants reported;<break/>IB: <italic toggle="yes">MET</italic><break/>copy number gain (8 copies)<break/><italic toggle="yes">EGFR</italic><break/>copy number gain (3 copies)<break/><italic toggle="yes">BRAF</italic><break/>copy number gain (5 copies)<break/><italic toggle="yes">MYC</italic><break/>copy number gain (3 copies)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">F</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">70</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">adenocarcinoma component:<break/>rearranged nuclei: 26%<break/>pattern: inversion<break/>squamous cell carcinoma component:<break/>rearranged nuclei: 6%<break/><italic toggle="yes">ALK</italic> negative</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Adenocarcinoma component:<break/>14% 4&#8211;7 copies<break/>Squamous cell carcinoma component:<break/>not detected</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">negative</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IA: no variants reported;<break/>IB: no variants reported</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">M</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">64</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">rearranged nuclei: 18%<break/>pattern: 5&#8242; deletion + inversion</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">not detected</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">negative</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IA: no variants reported;<break/>IB: <italic toggle="yes">TP53</italic><break/>p.P152Rfs</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">F</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">75</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">rearranged nuclei: 17%<break/>pattern: 5&#8242; deletion + translocation + inversion</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">13% 4 copies;<break/>12% 5&#8211;6 copies;<break/>1% 7&#8211;8 copies;<break/>5% more than 10 copies</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">negative</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IA: no variants reported;<break/>IB: <italic toggle="yes">MYC</italic><break/>copy number gain<break/>(22 copies)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">M</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">78</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">rearranged nuclei: 60%<break/>pattern: 5&#8242; deletion</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4% 4 copies; 4% 5 copies</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">negative</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IA: no variants reported;<break/>IB: no variants reported</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">M</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">63</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">moderately differentiated component:<break/>rearranged nuclei: 4%<break/><italic toggle="yes">ALK</italic> negative<break/>poorly differentiated component:<break/>rearranged nuclei: 16%<break/>pattern: translocation + inversion</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Moderately differentiated component:<break/>22% 4 copies;<break/>18% 5&#8211;8 copies<break/>Poorly differentiated component:<break/>10% 4 copies;<break/>2% 5&#8211;6 copies</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">negative</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IA: no variants reported;<break/>IB: no variants reported</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">11.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">F</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">79</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">rearranged nuclei: 4%<break/><italic toggle="yes">ALK</italic> negative<break/>(38% positive in analysis with the break apart probe; population not found in further sections)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4% 4 copies;<break/>2% 7&#8211;8 copies</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Negative, 100 positive nuclei</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IA: no variants reported;<break/>IB: no variants reported</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">F</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">77</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">rearranged nuclei: 4%<break/><italic toggle="yes">ALK</italic> negative<break/>(according to valid guidelines)<break/>abnormal signal configuration:<list list-type="simple"><list-item><label>-</label><p>28% isolated 5&#8242; green signal co-localizing with blue signal, isolated blue signal</p></list-item><list-item><label>-</label><p>32% isolated 5&#8242; green signal co-localizing with blue signal</p></list-item><list-item><label>-</label><p>14% isolated 5&#8242; green signal co-localizing with blue signals, isolated blue signal; another copy isolated 5&#8242; green signal co-localizing with blue signal</p></list-item></list></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">not detected</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">positive</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IA: <italic toggle="yes">EML4, ALK</italic><break/>fusion transcript<break/>IB: no variants reported</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">13.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">F</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">71</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ALK/EML4 probe not used<break/>rearranged nuclei: 2% using the ALK break apart probe<list list-type="simple"><list-item><label>-</label><p>1% isolated 3&#8242; orange signal, isolated 5&#8242; green signal</p></list-item><list-item><label>-</label><p>1% isolated 3&#8242; orange signal</p></list-item></list></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">not detected</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">positive</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IA: <italic toggle="yes">CSFT3, ALK</italic><break/>fusion transcript<break/>IB: no variants reported</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">14.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">F</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">56</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">rearranged nuclei: 50%<break/>pattern: inversion</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">not detected</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">positive</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IA: <italic toggle="yes">EML4, ALK</italic><break/>fusion transcript<break/>IB: no variants reported</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">15.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">F</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">73</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">rearranged nuclei: 48%<break/>pattern: interstitial deletion + inversion</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">not detected</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">positive</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IA: <italic toggle="yes">EML4, ALK</italic><break/>fusion transcript<break/>IB: EGFR<break/>copy number gain (3 copies)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">16.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">M</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">48</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">rearranged nuclei: 62%<break/>pattern: 5&#8242; deletion + interstitial deletion</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">not detected</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">positive</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IA: <italic toggle="yes">HIP1, ALK</italic><break/>fusion transcript<break/>IB: no variants reported</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">17.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">F</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">64</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">rearranged nuclei: 90%<break/>pattern: interstitial deletion</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">positive nuclei display up to 4 rearranged signals</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">positive</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IA: <italic toggle="yes">EML4, ALK</italic><break/>fusion transcript<break/>IB: no variants reported</td></tr></tbody></table></table-wrap></floats-group></article></pmc-articleset>